Menu
 
Research menu
Jump to menu

Publications:  Prof John Gribben

Seymour JF, Gribben JG, Davids MS, Mato A, Sharman JP, Cyr A, Bartkus C, Pena G et al.(2020). Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings. Blood vol. 136, (Supplement 1) 37-38.
10.1182/blood-2020-134938
Bloehdorn J, Braun A, Jebaraj BMC, Taylor-Weiner A, Robrecht S, Krzykalla J, Holzmann K, Johnston H et al.(2020). Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia. Blood vol. 136, (Supplement 1) 12-13.
10.1182/blood-2020-141552
Merlini G, Gribben J, Macintyre E, Piggin M, Doeswijk R(2020). Access to Affordable Orphan Medicines in Europe: An EHA Position Paper. Hemasphere vol. 4, (5)
10.1097/HS9.0000000000000477
Roy-Luzarraga M, Abdel-Fatah T, Reynolds LE, Clear A, Taylor JG, Gribben JG, Chan S, Jones L et al.(2020). Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer. JAMA network open vol. 3, (10)
10.1001/jamanetworkopen.2020.19304
Hagenbeek A, Gribben J, Jäger U, Kapitein P, Merlini G, Piggin M, Groot CAU-D, Doeswijk R(2020). Fair Pricing of Innovative Medicines: An EHA Position Paper. Hemasphere vol. 4, (5)
10.1097/HS9.0000000000000488
Jäger U, Kapitein P, Gribben J(2020). Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper. Hemasphere vol. 4, (5)
10.1097/HS9.0000000000000474
La Rosee P, Graeven U, Leonard JP, Gribben J, Zhang H, Nowakowski G, Izutsu K, Fowler NH et al. (2020). Subgroup analyses of patients aged >= 70 years in AUGMENT: Phase III randomized study of Lenalidomide plus rituximab (R-2) vs rituximab plus placebo (R-placebo) in patients with Relapsed/Refractory (R/R) indolent Non-Hodgkin Lymphoma (iNHL). ONCOLOGY RESEARCH AND TREATMENT. vol. 43, 68-68.
Ball J, Clear A, Aries J, Charrot S, Besley C, Mee M, Stagg A, Lindsay J et al.(2020). Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD. Blood
10.1182/blood.2020005170
https://qmro.qmul.ac.uk/xmlui/handle/123456789/67084
Anthias C, Apperley J, Bloor A, Byrne J, Collin M, Crawley C, Craddock C, Finnegan D et al.(2020). Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. Bone Marrow Transplantation vol. 55, (9) 1840-1843.
10.1038/s41409-020-0870-0
Wong PP, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O et al.(2020). Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells. Cell vol. 181, (6) 1346-1363.e21.
10.1016/j.cell.2020.02.003
Macintyre E, Gribben J, Döhner K(2020). EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper. Hemasphere vol. 4, (3)
10.1097/HS9.0000000000000412
Waclawiczek A, Hamilton A, Rouault-Pierre K, Abarrategi A, Albornoz MG, Miraki-Moud F, Bah N, Gribben J et al.(2020). Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia. Journal of Clinical Investigation vol. 130, (6) 3038-3050.
10.1172/JCI133187
Townsend W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Zhang Z, Rufibach K et al. (2020). Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study. JOURNAL OF CLINICAL ONCOLOGY. vol. 38,
Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V et al.(2020). Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients. British Journal of Haematology
10.1111/bjh.16852
Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M, Krause DS(2020). Bone marrow niches in haematological malignancies. Nature Reviews Cancer vol. 20, (5) 285-298.
10.1038/s41568-020-0245-2
Gribben JG(2020). Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?. British Journal of Haematology vol. 189, (4) 603-604.
10.1111/bjh.16470
Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ et al.(2020). Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica vol. 105, (5) 1379-1390.
10.3324/HAEMATOL.2019.217307
Ghazaly EA, Miraki-Moud F, Smith P, Gnanaranjan C, Koniali L, Oke A, Saied MH, Petty R et al.(2020). Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function. J Biol Chem vol. 295, (16) 5496-5508.
10.1074/jbc.RA119.010467
Dexter T, Aries J, Sevillano B, Gribben J, Oakervee H, Cavenagh J, Smith M, Wrench B (2020). Antibody immunotherapy treatment for adults with B-acute lymphoblastic leukaemia-a real-world analysis. BRITISH JOURNAL OF HAEMATOLOGY. vol. 189, 186-186.
Pieri CA, Roberts N, Gribben J, Manisty C(2020). Graft-versus-host disease: a case report of a rare but reversible cause of constrictive pericarditis. Eur Heart J Case Rep vol. 4, (2) 1-5.
10.1093/ehjcr/ytaa009
Gribben JG, de Vries E, Cherny NI, Sonneveld P(2020). Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next?. Hemasphere vol. 4, (2)
10.1097/HS9.0000000000000354
Gribben J, Macintyre E, Sonneveld P, Doorduijn J, Gisselbrecht C, Jäger U, Le Gouill S, Rule S et al.(2020). Reducing Bureaucracy in Clinical Research: A Call for Action. Hemasphere vol. 4, (2)
10.1097/HS9.0000000000000352
Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I et al.(2020). Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma. Oncogene vol. 39, (14) 2934-2947.
10.1038/s41388-020-1183-x
Di Mambro A, Arroyo-Berdugo Y, Calle Y, Wrench B, Gribben J, Esposito MT (2020). Targeting SET-PP2A complex as a new avenue of treatment for Mixed Lineage Leukemia (MLL) treatment. BRITISH JOURNAL OF HAEMATOLOGY. vol. 189, 51-52.
Prynn N, Jackson G, Gribben J, Follows G, McDougall L (2020). The Haematology Summit 2014-2019: evolution of a national medical education programme. BRITISH JOURNAL OF HAEMATOLOGY. vol. 189, 62-63.
Munir T, Rawstron A, Brock K, Munoz-Vicente S, Yates F, Bishop R, MacDonald D, Fegan C et al. (2020). Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study. LEUKEMIA & LYMPHOMA. vol. 61, 227-228.
Krysov S, Odabashian M, Carlotti E, Araf S, Okosun J, Spada F, Gribben J, Forconi F et al.(2020). IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. Blood vol. 135, (11) 834-844.
10.1182/blood.2019002279
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63344
Wu Y, Chang YM, Polton G, Stell AJ, Szladovits B, Macfarlane M, Peters LM, Priestnall SL et al.(2020). Gene Expression Profiling of B Cell Lymphoma in Dogs Reveals Dichotomous Metabolic Signatures Distinguished by Oxidative Phosphorylation. Frontiers in Oncology vol. 10,
10.3389/fonc.2020.00307
Gribben JG(2020). Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. British Journal of Haematology vol. 188, (6) 844-851.
10.1111/bjh.16345
Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E et al.(2020). MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia vol. 34, (2) 522-532.
10.1038/s41375-019-0559-9
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D et al.(2020). A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Haematologica vol. 105, (4) E164-E168.
10.3324/haematol.2019.223743
Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M et al.(2020). Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol vol. 7, (1) e50-e60.
10.1016/S2352-3026(19)30208-X
Wodehouse T, Demopoulos M, Petty R, Miraki-Moud F, Belhaj A, Husband M, Fulton L, Randive N et al.(2019). A randomized pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling during surgery. Pain vol. 160, (12) 2691-2698.
10.1097/j.pain.0000000000001677
Gribben J, Merlini G, Hagenbeek A(2019). Here to Stay: Biosimilars in Hematology. Hemasphere vol. 3, (6)
10.1097/HS9.0000000000000323
Goulart MR, Hlavaty SI, Chang YM, Polton G, Stell A, Perry J, Wu Y, Sharma E et al.(2019). Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells. Scientific Reports vol. 9, (1)
10.1038/s41598-019-40285-3
Wu Y, Chang YM, Stell AJ, Priestnall SL, Sharma E, Goulart MR, Gribben J, Xia D et al.(2019). Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice. Scientific Reports vol. 9, (1)
10.1038/s41598-019-50065-8
Taylor JG, Clear AJ, Truelove E, Calaminici M, Gribben JG (2019). Beyond Exhaustion: The PDL1-PD1 Axis Shapes the Classical Hodgkin Lymphoma Microenvironment. Blood. vol. 134, 658-658.
10.1182/blood-2019-125247
Sanderson R, Romero-Toledo A, Gribben JG (2019). CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS. Blood. vol. 134, 249-249.
10.1182/blood-2019-125647
Saunderson EA, Rouault-Pierre K, Gribben JG, Ficz G(2019). CRISPR/Cas9-Targeted De Novo DNA Methylation Is Maintained and Impacts the Colony Forming Potential of Human Hematopoietic CD34+ Cells. Blood vol. 134, (Supplement_1) 2517-2517.
10.1182/blood-2019-130267
Schönland SO, Iacobelli S, Koster L, Blaise D, Potter M, Cornelissen JJ, Chevallier P, Mayer J et al. (2019). Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT. Blood. vol. 134, 324-324.
10.1182/blood-2019-128795
Aries J, Charrot S, Ball J, Mee M, Theocharidis S, Van Gassen S, Iqbal S, Gribben JG et al. (2019). Integrated Immune Signature Analyses Identifies Evolution of Distinct Immunoregulatory Cell Populations Which Control Alloreactivity after Allogeneic HSCT. Blood. vol. 134, 595-595.
10.1182/blood-2019-124875
https://qmro.qmul.ac.uk/xmlui/handle/123456789/67024
Bewicke-Copley F, Korfi K, Araf S, Kumar EA, Cummin TEC, Ashton-Key M, Barrans S, Van Hoppe S et al.(2019). Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel. Blood vol. 134, (Supplement_1) 2769-2769.
10.1182/blood-2019-124352
Edelmann J, Dokal A, Holzmann K, Britton DJ, Vilventhraraja E, Smith RJ, Cragg MS, Braun A et al.(2019). Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis. Blood vol. 134, (Supplement_1) 1579-1579.
10.1182/blood-2019-128704
Trn¿ný M, Leonard JP, Zhang H, Nowakowski G, Izutsu K, Fowler NH, Thieblemont C, Zinzani PL et al.(2019). Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood vol. 134, (Supplement_1) 347-347.
10.1182/blood-2019-122461
Sehn LH, Trn¿ný M, Bouabdallah K, Dueck G, Gribben JG, Lugtenburg PJ, Salles GA, Knapp A et al.(2019). Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study. Blood vol. 134, (Supplement_1) 2822-2822.
10.1182/blood-2019-123422
Truelove E, Seymour F, Taylor JG, Calaminici M, Clear AJ, Gribben JG(2019). The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets. Blood vol. 134, (Supplement_1) 5240-5240.
10.1182/blood-2019-130712
Romero-Toledo A, Sanderson R, Gribben JG(2019). Treatment with Acalibrutinib, Ibrutinib and CD19 CAR T Cells Restore the Number of Granulocytic Myeloid Derived Supressor Cells in CLL-Bearing Mice. Blood vol. 134, (Supplement_1) 3032-3032.
10.1182/blood-2019-126697
Hayden PJ, Eikema D-J, Koster L, Goldschmidt H, Blaise D, Potter M, Touzeau C, Huynh A et al.(2019). Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. Blood vol. 134, (Supplement_1) 4575-4575.
10.1182/blood-2019-127166
Crombie JL, Letai A, Gribben JG(2019). Lymphoma genetics. Molecular Hematology 4e,
Gribben JG(2019). The molecular biology of chronic lymphocytic leukemia. Molecular Hematology 4e,
Pinto A, Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F et al. (2019). LENALIDOMIDE/RITUXIMAB (R2) VERSUS RITUXIMAB/PLACEBO EFFICACY BY POD24 STATUS AND TIME TO NEXT TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL (AUGMENT). HAEMATOLOGICA. vol. 104, 7-8.
Savoie ML, Davies JK, Cavenagh J, Oakervee H, Sive J, Smith M, Anderson D, Gribben J et al. (2019). Low treatment related mortality and relapse leading to excellent outcomes after allogeneic transplantation for acute lymphoblastic leukaemia using a non-myeloablative conditioning without T CELL depletion. BONE MARROW TRANSPLANTATION. vol. 54, 144-145.
Aries J, Ball J, Charrot S, Mee M, Van Gassen S, Iqbal S, Gribben J, Davies J (2019). Novel mass cytometry analysis identifies reciprocal changes in NKREG and CD4EM as the dominant early immune reconstitution signature associated with subsequent acute GVHD after RIC-AHST. BONE MARROW TRANSPLANTATION. vol. 54, 117-118.
Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A et al.(2019). Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature vol. 570, (7762) 474-479.
10.1038/s41586-019-1252-x
Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA et al.(2019). Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood vol. 133, (26) 2765-2775.
10.1182/blood-2019-01-896290
Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F, Scheliga A et al.(2019). AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. Hematological Oncology vol. 37, 114-115.
10.1002/hon.75_2629
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga A et al.(2019). AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. Hematological Oncology vol. 37, 227-229.
10.1002/hon.42_2630
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al.(2019). Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (Leukemia, (2018), 32, 5, (1261-1265), 10.1038/s41375-018-0043-y). Leukemia vol. 33, (6)
10.1038/s41375-019-0425-9
Leonard JP, Trn¿ny M, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga A et al.(2019). HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO. Hematological Oncology vol. 37, 232-234.
10.1002/hon.45_2630
Korfi K, Araf S, Bewicke¿Copley F, Kumar E, Cummin T, Ashton¿Key M, Barrans S, Van Hoppe S et al.(2019). LONGITUDINAL ANALYSES OF DIAGNOSTIC‐RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. Hematological Oncology vol. 37, 142-143.
10.1002/hon.100_2629
Jurgensen-Rauch A, Gibbs S, Farrell M, Cavenagh J, Eccersley L, Gribben J, Hallam S, Oakervee H et al.(2019). PF642 REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS – A SINGLE CENTRE EXPERIENCE. HemaSphere vol. 3, (S1)
10.1097/01.hs9.0000560852.21697.ea
Thieblemont C, Leonard J, Trneny M, Izutsu K, Fowler N, Hong X, Zhang H, Offner F et al.(2019). POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). Hematological Oncology vol. 37, 226-227.
10.1002/hon.41_2630
Romero-Toledo A, Schwarzbich M, Sanderson R, Gribben J(2019). PS1135 MONOCYTIC BUT NOT GRANULOCYTIC MDSCS INCREASE WITH IBRUTINIB BUT NOT ACALABRUTINIB TREATMENT IN EM-TCL1 MICE WITH CLL, SUGGESTING A ROLE FOR ITK INHIBITION IN MONOCYTIC MDSCS. HemaSphere vol. 3, (S1)
10.1097/01.hs9.0000562824.01603.f1
Heward J, Koniali L, D¿Avola A, Close K, Yeomans A, Johnson P, Okosun J, Neve R et al.(2019). S844 KDM5 INHIBITION OFFERS A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF KMT2D MUTANT LYMPHOMAS. HemaSphere vol. 3, (S1) 376-377.
10.1097/01.hs9.0000561656.72982.67
Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E et al.(2019). Autologous stem cell transplantation in refractory Crohn's disease - Low intensity therapy evaluation (ASTIClite): Study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology vol. 19, (1)
10.1186/s12876-019-0992-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58514
Gribben JG, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga AAS, Nowakowski GS et al.(2019). Efficacy and time to next treatment following lenalidomide/rituximab (R 2 ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT). Journal of Clinical Oncology vol. 37, (15_suppl) 7514-7514.
10.1200/jco.2019.37.15_suppl.7514
Gribben JG, Izutsu K, Fowler NH, Hong X, Zhang H, Offner F, Scheliga AAS, Nowakowski GS et al. (2019). Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT). JOURNAL OF CLINICAL ONCOLOGY. vol. 37,
Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G, Papaemmanuil E, Campbell P, Gribben J et al.(2019). Single cell analysis of clonal architecture in acute myeloid leukaemia. Leukemia vol. 33, (5) 1113-1123.
10.1038/s41375-018-0319-2
Sun D, Stopka-Farooqui U, Barry S, Aksoy E, Parsonage G, Vossenkämper A, Capasso M, Wan X et al.(2019). Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation. Cell Reports vol. 27, (5) 1461-1471.e4.
10.1016/j.celrep.2019.04.014
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57415
Zhang T, Guan X-W, Gribben JG, Liu F-T, Jia L(2019). Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma. Cell Death Dis vol. 10, (5)
10.1038/s41419-019-1563-8
BARRY S, Sun D, Stopka-Farooqui U, Aksoy E, Parsonage G, Vossenkamper A, Capasso M, Wan X et al.(2019). SAT-LB056 Is AIP a Tumor Suppressor or an Oncogene? AIP as a Novel Regulator of the Oncogene BCL6 in Diffuse Large B Cell Lymphoma. Journal of the Endocrine Society vol. 3, (Suppl 1)
10.1210/js.2019-sat-lb056
Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol A-M, Montoto S, Gribben JG, Calaminici M et al.(2019). Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. Leuk Lymphoma vol. 60, (4) 1087-1091.
10.1080/10428194.2018.1512711
Munir T, Rawstron A, Brock K, Vicente SM, Yates F, Bishop R, Macdonald D, Fegan C et al. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. BRITISH JOURNAL OF HAEMATOLOGY. vol. 185, 25-25.
Gribben J, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F et al. (2019). Phase III Randomized AUGMENT Study of Lenalidomide/Rituximab vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. vol. 185, 79-79.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F et al.(2019). AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. Journal of Clinical Oncology vol. 37, (14) 1188-1199.
10.1200/JCO.19.00010
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O et al.(2019). Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol vol. 20, (1) 43-56.
10.1016/S1470-2045(18)30788-5
Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R, Boucher R, MacDonald D et al.(2019). Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: The CLARITY study. Journal of Clinical Oncology vol. 37, (30) 2722-2729.
10.1200/JCO.19.00894
Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, Natkunam Y, Calaminici M et al.(2019). Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: A study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology vol. 37, (35) 3359-3368.
10.1200/JCO.19.00743
Taylor JG, Clear A, Calaminici M, Gribben JG(2019). Programmed cell death protein-1 (PD1) expression in the microenvironment of classical hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy. Haematologica vol. 104, (1) e42-e44.
10.3324/haematol.2018.204818
McClanahan F, Gribben J(2019). The Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. Handbook of Immunosenescence,
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben JG, Zinzani PL (2018). A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies. Blood. vol. 132, 4161-4161.
10.1182/blood-2018-99-112808
Leonard JP, Trn¿ný M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F et al. (2018). AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. vol. 132, 445-445.
10.1182/blood-2018-99-110861
Edelmann J, Britton DJ, Vilventhraraja E, Dokal A, Holzmann K, Cragg MC, Braun A, Cutillas P et al. (2018). Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway. Blood. vol. 132, 588-588.
10.1182/blood-2018-99-116490
Clear AJ, D'Avola A, Agrawal SG, Rassenti LZ, Kipps TJ, Gribben JG, Riches J (2018). B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells. Blood. vol. 132, 3121-3121.
10.1182/blood-2018-99-112860
Seymour F, Cavenagh J, Gribben JG (2018). Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance. Blood. vol. 132, 58-58.
10.1182/blood-2018-99-114102
Truelove E, Seymour F, Matthews J, Gribben JG (2018). Deep Phenotypic Analysis Reveals a Monocyte Subpopulation Predictive of Relapse/Refractory Diffuse Large B-Cell Lymphoma. Blood. vol. 132, 2863-2863.
10.1182/blood-2018-99-119756
Sanderson R, Romero-Toledo A, Gribben JG(2018). Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model. Blood vol. 132, (Supplement 1) 4537-4537.
10.1182/blood-2018-99-111180
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O et al. (2018). Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE. Blood. vol. 132, 691-691.
10.1182/blood-2018-99-111370
Hillmen P, Rawstron A, Brock K, Munoz Vicente S, Yates F, Bishop R, Macdonald D, Fegan C et al. (2018). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. Blood. vol. 132, 182-182.
10.1182/blood-2018-182
Seymour F, Young MH, Tometsko M, Cavenagh J, Thompson EG, Whalen E, Danziger SA, Fitch A et al. (2018). Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab. Blood. vol. 132, 3296-3296.
10.1182/blood-2018-99-114453
Odabashian M, Carlotti E, Araf S, Okosun J, Forconi F, Stevenson FK, Gribben JG, Calaminici M et al. (2018). Immunoglobulin Variable Region Gene Sequences Reveal N-Glycosylation Motifs As an Early and Stable Event in Follicular Lymphoma Pathology. Blood. Conference: Search Results Web results ASH Meeting on Lymphoma Biology vol. 132, 4101-4101.
10.1182/blood-2018-99-112397
Ribrag V, Morschhauser F, McKay P, Salles GA, Batlevi CL, Schmitt A, Tilly H, Cartron G et al.(2018). Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Blood vol. 132, (Supplement 1) 4196-4196.
10.1182/blood-2018-99-113411
Schwarzbich M-A, Romero-Toledo A, Gribben JG (2018). Modulation of T-Cell Function and Immune Phenotype in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Ibrutinib. Blood. vol. 132, 3138-3138.
10.1182/blood-2018-99-118059
Schwarzbich M-A, Romero-Toledo A, Frigault M, Gribben JG(2018). Modulation of T-Cell Function in the Microenvironment of Emu-TCL1 CLL Bearing Mice By Btki Appears Independent of ITK. Blood vol. 132, (Supplement 1) 3139-3139.
10.1182/blood-2018-99-116444
Townsend W, Buske C, Cartron G, Cunningham D, Dyer MJ, Gribben JG, Hess G, Ishikawa T et al. (2018). Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study. Blood. vol. 132, 1597-1597.
10.1182/blood-2018-99-115167
Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr P, Anz B, Simpson D et al.(2018). Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison. Blood vol. 132, (Supplement 1) 5565-5565.
10.1182/blood-2018-99-111369
Taylor JG, Clear AJ, Matthews J, Calaminici M, Gribben JG (2018). The Treg/Th17 Axis Is Skewed in Classical Hodgkin Lymphoma By PDL1+Ve but Not PDL1-Ve Lymphoma Cells and By Lymphoma MHC Class 2 Expression. Blood. vol. 132, 4124-4124.
10.1182/blood-2018-99-119126
Freeman CL, Böttcher S, De la Serna J, Delgado J, Falzetti F, Gobbi M, Lejniece S, Di Bernardo MC et al. (2018). Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial. Blood. vol. 132, 4419-4419.
10.1182/blood-2018-99-118238
McDonald A, Thomas E, Daigle S, Morschhauser F, Salles G, Ribrag V, McKay P, Tilly H et al. (2018). Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. Blood. vol. 132, 4097-4097.
10.1182/blood-2018-99-115132
Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N et al.(2018). Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology vol. 5, (11) e563-e598.
10.1016/S2352-3026(18)30051-6
Robak T, Burger JA, Tedeschi A, Barr PM, Owen C, Bairey O, Hillmen P, Simpson D et al.(2018). Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. Am J Hematol vol. 93, (11) 1402-1410.
10.1002/ajh.25259
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben J, Zinzani PL(2018). 1014PD Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies. Annals of Oncology vol. 29, viii362-viii363.
10.1093/annonc/mdy286.010
Jurczak W, Rule S, Townsend W, Tucker D, Sarholz B, Scheele J, Gribben J, Zinzani PL (2018). Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies. ANNALS OF ONCOLOGY. vol. 29,
Gribben JG(2018). No longer too exhausted to run. Blood vol. 132, (5) 464-465.
10.1182/blood-2018-06-851642
Cheson BD, Chua N, Mayer J, Dueck G, Trn¿ný M, Bouabdallah K, Fowler N, Delwail V et al.(2018). Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. Journal of Clinical Oncology vol. 36, (22) 2259-2266.
10.1200/JCO.2017.76.3656
Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S et al.(2018). Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia vol. 32, (8) 1818-1822.
10.1038/s41375-018-0032-1
Gribben JG(2018). How and when I do allogeneic transplant in CLL. Blood vol. 132, (1) 31-39.
10.1182/blood-2018-01-785998
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward J et al.(2018). Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia vol. 32, (5) 1258-1263.
10.1038/s41375-018-0043-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36269
Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA(2018). Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Front Immunol vol. 9, 646-646.
10.3389/fimmu.2018.00646
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53523
Munir T, Rawstron A, Brock K, Vicente SM, Yates F, Bishop R, Fegan C, Macdonald D et al. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. BRITISH JOURNAL OF HAEMATOLOGY. vol. 181, 34-35.
Dürr C, Hanna BS, Schulz A, Lucas F, Zucknick M, Benner A, Clear A, Ohl S et al.(2018). Tumor necrosis factor receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin. Haematologica vol. 103, (4) 688-697.
10.3324/haematol.2017.177808
Griessinger E, Vargaftig J, Horswell S, Taussig DC, Gribben J, Bonnet D(2018). Acute myeloid leukemia xenograft success prediction: Saving time. Experimental Hematology vol. 59, 66-71.e4.
10.1016/j.exphem.2017.12.002
Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, Moreno C, Stilgenbauer S(2018). Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. British Journal of Haematology vol. 180, (5) 666-679.
10.1111/bjh.15080
Gribben JG(2018). Chapter 80 Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma. Hematology,
Casado P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Iqbal S et al.(2017). Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells. Leukemia
10.1038/leu.2017.349
Warrick N, Miraki-Moud F, Aicher A, McNaughton LA, Casado-Izquierdo P, Nagano A, Carroll R, Bonnet D et al. (2017). Adipocyte Induced Antagonism of ALL Growth Highlights a Novel Inhibitory Niche and Potential Therapeutic Opportunity. BLOOD. vol. 130,
Araf S, Wang J, Korfi K, Pangault C, Kotsiou E, Rio-Machin A, Rahim T, Heward JA et al. (2017). Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma. BLOOD. vol. 130,
Ball JA, Clear AJ, Calaminici M, Stagg A, Lindsay J, Gribben JG, Davies J (2017). Human Gastro-Intestinal Graft-VersusHost Disease Is Mediated By Retinoic Acid-Responsive CD8(+)Effector T-Cells Under IL-23 Polarising Conditions. BLOOD. vol. 130,
Zhang J, Reddy A, Davis N, Moffitt A, Love C, Waldrop A, Leppa S, Pasanen A et al. (2017). Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa. BLOOD. vol. 130,
Araf S, Korfi K, Nagano A, Cummin TEC, Bentley M, Thorner AR, Ashton-Key M, Calaminici M et al. (2017). Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse. BLOOD. vol. 130,
Dreger P, Koster L, Passweg JR, Collin M, Scheid C, Charbonnier A, Ciceri F, Thieblemont C et al. (2017). Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties. BLOOD. vol. 130,
Pearce OMT, Delaine-Smith R, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D et al.(2017). Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov
10.1158/2159-8290.CD-17-0284
https://qmro.qmul.ac.uk/xmlui/handle/123456789/30984
Gascoyne RD, Nadel B, Pasqualucci L, Fitzgibbon J, Payton JE, Melnick A, Weigert O, Tarte K et al.(2017). Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological Oncology vol. 35, (4) 397-407.
10.1002/hon.2411
Saunderson EA, Stepper P, Gomm JJ, Hoa L, Morgan A, Allen MD, Jones JL, Gribben JG et al.(2017). Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors. Nature Communications vol. 8, (1)
10.1038/s41467-017-01078-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/29503
Munoz-Vicente S, Bishop R, Hillmen P, Munir T, Rawstron A, Brock K, Fox C, Gribben J et al. (2017). The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy. LEUKEMIA & LYMPHOMA. vol. 58, 239-239.
Edelmann J, Lu C, Klymenko T, Vilventhraraja E, Estenfelder S, Tausch E, Stilgenbauer S, Mark C et al. (2017). p.P2514fs mutant NOTCH1 has longer lasting transcription factor activity due to slower inactivation and degradation. LEUKEMIA & LYMPHOMA. vol. 58, 67-68.
Di Tullio A, Rouault-Pierre K, Abarrategi A, Mian S, Grey W, Gribben J, Stewart A, Blackwood E et al.(2017). The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia. Nat Commun vol. 8, (1) 1679-1679.
10.1038/s41467-017-01834-4
https://qmro.qmul.ac.uk/xmlui/handle/123456789/34404
DAVIES JK, Hassan S, Sarker S, Besley C, Oakervee H, Smith M, Taussig D, Gribben JG et al.(2017). Durable graft-versus-leukaemia effects without donor lymphocyte infusions- results of a Phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia. British Journal of Haematology
10.1111/bjh.14980
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25815
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A et al.(2017). Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell vol. 171, (2) 481-494.e15.
10.1016/j.cell.2017.09.027
Munir T, Howard DR, McParland L, Pocock C, Rawstron AC, Hockaday A, Varghese A, Hamblin M et al.(2017). Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. Leukemia vol. 31, (10) 2085-2093.
10.1038/leu.2017.65
Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Montaner B, Chakravarty P et al.(2017). Increased Vascular Permeability in the Bone Marrow Microenvironment Contributes to Disease Progression and Drug Response in Acute Myeloid Leukemia. Cancer Cell vol. 32, (3) 324-341.e6.
10.1016/j.ccell.2017.08.001
https://qmro.qmul.ac.uk/xmlui/handle/123456789/34506
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J et al.(2017). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia vol. 32, (2) 364-375.
10.1038/leu.2017.255
https://qmro.qmul.ac.uk/xmlui/handle/123456789/54655
Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E et al.(2017). Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica vol. 102, (8) 1413-1423.
10.3324/haematol.2017.165415
Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO et al.(2017). Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. Bone Marrow Transplant vol. 52, (8) 1120-1125.
10.1038/bmt.2017.88
Jagasia M, Beohou E, van der Werf S, Niederwieser D, Dreger P, Meijer E, Chevallier P, Sengeloev H et al. (2017). Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: an EBMT registry analyses. BONE MARROW TRANSPLANTATION. vol. 52, S83-S83.
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K et al.(2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of oncology : official journal of the European Society for Medical Oncology vol. 28, (7) 1436-1447.
10.1093/annonc/mdx097
Dreger P, Boumendil A, Koster L, Scheid C, Passweg J, Veelken H, Cahn Y, Collin M et al. (2017). No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties. BONE MARROW TRANSPLANTATION. vol. 52, S424-S425.
Taylor JG, Seddon T, Alizadeh K, Agrawal C, Kempster L, Gribben JG, Agrawal SG (2017). Single centre experience of ZarzioTM biosimilar Granulocyte-colony stimulating factor (GCSF) for the mobilisation of healthy donors demonstrates good leukapheresis yields and safety profile at 24 month median follow-up. BONE MARROW TRANSPLANTATION. vol. 52, S145-S146.
Passaro D, Di Tullio A, Abarrategi A, Rouault-Pierre K, Foster K, Ariza-McNaughton L, Chakravarty P, Bhaw L et al. (2017). ACUTE MYELOID LEUKEMIA ALTERS THE PERMEABILITY OF THE BONE MARROW VASCULAR MICROENVIRONMENT, FOSTERING DISEASE PROGRESSION AND DRUG RESISTANCE. HAEMATOLOGICA. vol. 102, 78-78.
Besley C, Kotsiou E, Petty R, Sangaralingam A, Chelala C, Ghazaly E, LeDieu R, Gribben J et al. (2017). ALLORESPONSES OF HUMAN T-CELLS FROM ADULT PERIPHERAL BLOOD AND UMBILICAL CORD BLOOD ARE DIFFERENTIALLY IMPACTED BY LENALIDOMIDE - IMPLICATIONS FOR AHSCT. HAEMATOLOGICA. vol. 102, 638-638.
Seymour F, Cavenagh J, Gribben J (2017). CYTOTOXIC LYMPHOCYTES IN NEWLY DIAGNOSED MYELOMA HAVE REVERSIBLE FUNCTIONAL AND PHENOTYPIC ABNORMALITIES THAT MAY OFFER THERAPUTIC OPPORTUNITIES. HAEMATOLOGICA. vol. 102, 498-498.
Vilventhraraja E, Gribben J, Braun A (2017). INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL. HAEMATOLOGICA. vol. 102, 567-567.
Dokal A, Gribben J, Cutillas P (2017). MICROENVIRONMENT SECRETED PROTEINS MEDIATE RESISTANCE TO TARGETED THERAPY IN PRIMARY AML CELLS. HAEMATOLOGICA. vol. 102, 358-358.
Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Wang J, Fischer K, Akylzhanova G, Edelmann J et al. (2017). NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES. HAEMATOLOGICA. vol. 102, 228-228.
Casado-Izquierdo P, Wilkes EH, Miraki-Moud F, Hadi MM, Rio-Machin A, Rajeeve V, Pike R, Sameena I et al. (2017). PHOSPHOPROTEOMICS AND MASS CYTOMETRY SIGNATURES OF PRIMARY AML CELL DIFFERENTIATION ARE ASSOCIATED WITH SENSITIVITY TO KINASE INHIBITORS. HAEMATOLOGICA. vol. 102, 203-203.
Hillmen P, Rawstron A, Munir T, Brock K, Vincente SM, Jefferson Y, Paterson K, Fox CP et al. (2017). THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY. HAEMATOLOGICA. vol. 102, 311-311.
Gribben JG(2017). Restoring leukemia cell function from the inside out. Blood vol. 129, (24) 3137-3138.
10.1182/blood-2017-04-776344
Baptista M, Tapia G, Muñoz¿Marmol A, Muncunill J, Montoto S, Gribben J, Calaminici M, Martinez A et al.(2017). APPLICATION OF CELL‐OF‐ORIGIN SUBTYPES DETERMINED BY DIGITAL GENE EXPRESSION IN HIV‐RELATED DIFFUSE LARGE B‐CELL LYMPHOMAS. Hematological Oncology vol. 35, (S2) 156-157.
10.1002/hon.2438_11
Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al.(2017). Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. The Lancet Gastroenterology & Hepatology vol. 2, (6) 399-406.
10.1016/S2468-1253(17)30056-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/24363
Edelmann J, Gribben JG(2017). Managing patients with TP53-deficient chronic lymphocytic leukemia. Journal of Oncology Practice vol. 13, (6) 371-377.
10.1200/JOP.2017.023291
Gribben JG(2017). The role of stem cell transplant for lymphoma in 2017. Hematol Oncol vol. 35 Suppl 1, 25-29.
10.1002/hon.2396
Radford J, Gribben J, Johnson PW, Malladi R, Neeson S, Asfaw B, O'Regan L, Law A et al.(2017). YourTreatmentChoices: FAST ACCESS TO TRIALS PROGRAMME. Hematological Oncology vol. 35, (S2) 272-273.
10.1002/hon.2438_145
Duncan M, Deane J, White PD, Ridge D, Roylance R, Korszun A, Chalder T, Bhui KS et al.(2017). A survey to determine usual care after cancer treatment within the United Kingdom National Health Service. BMC Cancer vol. 17, (186)
10.1186/s12885-017-3172-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/20541
Lucas FM, Gribben JG(2017). Aberrant Immunological Synapses Driven by Leukemic Antigen-Presenting Cells. Methods Mol Biol vol. 1584, 533-544.
10.1007/978-1-4939-6881-7_33
Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J et al.(2017). Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: Results from the CLL8 trial. Leukemia vol. 31, (3) 734-738.
10.1038/leu.2016.317
Abarrategi A, Foster K, Hamilton A, Mian SA, Passaro D, Gribben J, Mufti G, Bonnet D(2017). Versatile humanized niche model enables study of normal and malignant human hematopoiesis. Journal of Clinical Investigation vol. 127, (2) 543-548.
10.1172/JCI89364
Chanan-Khan A, Egyed M, Robak T, Martinelli de Oliveira FA, Echeveste MA, Dolan S, Desjardins P, Blonski JZ et al.(2017). Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). Leukemia vol. 31, (5) 1240-1243.
10.1038/leu.2017.47
https://qmro.qmul.ac.uk/xmlui/handle/123456789/35464
Dermit M, Casado P, Rajeeve V, Wilkes EH, Foxler DE, Campbell H, Critchlow S, Sharp TV et al.(2016). Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition. Oncogene
10.1038/onc.2016.435
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19702
Besley C, Kotsiou E, Petty R, Ajanthah S, Chelala C, Ghazaly E, Le Dieu R, Davies J et al. (2016). Alloresponses of Human T-Cells from Adult Peripheral Blood and Umbilical Cord Blood Are Differentially Impacted By Lenalidomide. Blood. vol. 128, 5714-5714.
10.1182/blood.v128.22.5714.5714
Casado P, Wilkes E, Hadi MM, Rajeeve V, Miraki-Moud F, Pike R, Del Rio-Machin A, Iqbal S et al. (2016). Differentiation Status Revealed By Shotgun Phosphoproteomics Determines Sensitivity of Primary AML Cells to Kinase Inhibitors. Blood. vol. 128, 840-840.
10.1182/blood.v128.22.840.840
Edelmann J, Klymenko T, Lu C, Vilventhraraja E, Estenfelder S, Tausch E, Beers SA, Stilgenbauer S et al. (2016). In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation. Blood. vol. 128, 971-971.
10.1182/blood.v128.22.971.971
Zhang J, Reddy A, Love C, Moffitt AB, Rajagopalan D, Leppä S, Pasanen A, Meriranta L et al. (2016). Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups. Blood. vol. 128, 1087-1087.
10.1182/blood.v128.22.1087.1087
Lo Celso C, Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L et al. (2016). Intravital Microscopy Reveals Fundamental Differences in the Interaction of Stem Cells and T Acute Lymphoblastic Leukaemia with the Bone Marrow Microenvironment. Blood. vol. 128, 5199-5199.
10.1182/blood.v128.22.5199.5199
Cheson BD, Trn¿ný M, Bouabdallah K, Dueck G, Gribben J, Lugtenburg PJ, Press O, Salles GA et al. (2016). Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. Blood. vol. 128, 615-615.
10.1182/blood.v128.22.615.615
Britton DJ, Wilkes E, Casado P, Rajeeve V, Fitzgibbon J, Gribben J, Cutillas PR (2016). Proteomic Analysis Directs Effective Drug Selection in Relapsed AML By Quantifying Drug Targets. Blood. vol. 128, 5265-5265.
10.1182/blood.v128.22.5265.5265
Vilventhraraja E, Klymenko T, Edelmann J, Gribben J, Ivanov A (2016). Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma. Blood. vol. 128, 1763-1763.
10.1182/blood.v128.22.1763.1763
Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E et al.(2016). Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation vol. 22, (12) 2117-2125.
10.1016/j.bbmt.2016.09.013
Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E et al.(2016). Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Annals of Hematology
10.1007/s00277-016-2878-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19680
Sarker SJ, Smith SK, Chowdhury K, Ganz PA, Zimmerman S, Gribben J, Korszun A(2016). Comparison of the impact of cancer between British and US long-term non-Hodgkin lymphoma survivors. Supportive Care in Cancer
10.1007/s00520-016-3454-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18960
Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS et al.(2016). High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia. Blood vol. 128, 2931-2940.
10.1182/blood-2016-04-712562
Salzer E, Cagdas D, Hons M, Mace EM, Garncarz W, Petronczki Ö, Platzer R, Pfajfer L et al.(2016). RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nature Immunology vol. 17, (12) 1352-1360.
10.1038/ni.3575
Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, Straszkowski L, Scott MK et al.(2016). T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature vol. 538, (7626) 518-522.
10.1038/nature19801
McClanahan F, Sharp TG, Gribben JG(2016). Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. Haematologica vol. 101, (10) 1144-1158.
10.3324/haematol.2016.145904
Navarro-Bailon A, Taylor JG, Matthews J, Montoto S, Gribben JG (2016). THE ROLE OF WATCH AND WAIT IN NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: SINGLE CENTRE DATA FROM THE MODERN ERA. HAEMATOLOGICA. vol. 101, 64-64.
Sehn LH, Chua N, Mayer J, Dueck G, Trn¿ný M, Bouabdallah K, Fowler N, Delwail V et al.(2016). Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol vol. 17, (8) 1081-1093.
10.1016/S1470-2045(16)30097-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58973
Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S et al.(2016). Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia vol. 30, (8) 1763-1766.
10.1038/leu.2016.41
https://qmro.qmul.ac.uk/xmlui/handle/123456789/28865
Eyre TA, Clifford R, Bloor A, Boyle L, Roberts C, Cabes M, Collins GP, Devereux S et al.(2016). NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. British Journal of Haematology
10.1111/bjh.14177
Hawkey CJ, Lindsay J, Gribben J(2016). In reply. JAMA - Journal of the American Medical Association vol. 315, (23) 2620-2621.
10.1001/jama.2016.4033
Schwarzbich MA, McClanahan F, DSc JGR(2016). Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies. Oncology (Williston Park, N.Y.) vol. 30, (6)
Vilventhraraja E, Gribben J, Ivanov A (2016). EXPLOITING OXIDATIVE PHOSPHORYLATION TO IMPROVE ANTIBODY THERAPY OF LYMPHOMA. HAEMATOLOGICA. vol. 101, 574-575.
Araf S, Wang J, Pangault C, Kotsiou E, Hoxha E, Iqbal S, Davies J, Johnson P et al. (2016). GENOMIC PROFILING REVEALS SPATIAL HETEROGENEITY IN FOLLICULAR LYMPHOMA: IMPLICATIONS FOR PRECISION MEDICINE. HAEMATOLOGICA. vol. 101, 270-270.
Dokal A, Gribben J, Cutillas P (2016). HETEROTYPIC SIGNALLING BETWEEN BONE MARROW STROMAL CELLS AND BLASTS PROVIDES INSIGHT INTO THE CELLULAR COMMUNICATION IN ACUTE MYELOID LEUKAEMIA. HAEMATOLOGICA. vol. 101, 369-369.
Petty R, Zhang X, Ivan C, Calin G, Gribben J, Le Dieu R (2016). MICRORNAS HSA-LET-7A AND MIR-142-3P IN T CELLS IN PATIENTS PRESENTING WITH ACUTE MYELOID LEUKAEMIA-A MEANS OF REPAIRING TUMOUR-INDUCED T CELL DEFECTS?. HAEMATOLOGICA. vol. 101, 364-365.
Trneny M, Bouabdallah K, Dueck G, Gribben J, Lugtenburg P, Press O, Salles G, Sehn L et al. (2016). OBINUTUZUMAB PLUS BENDAMUSTINE VERSUS BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE GADOLIN STUDY. HAEMATOLOGICA. vol. 101, 155-156.
Britton D, Casado P, Rajeeve V, Wilkes E, Smith R, Fitzgibbon J, Gribben J, Cutillas P (2016). PROTEOMIC ANALYSIS OF RELAPSE AML IDENTIFIES OPPORTUNITIES FOR THERAPEUTIC INTERVENTION IN INDIVIDUAL PATIENTS. HAEMATOLOGICA. vol. 101, 373-373.
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al.(2016). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma (vol 48, pg 183, 2016). NATURE GENETICS vol. 48, (6) 700-700.
10.1038/ng0616-700b
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Seraihi AFA et al.(2016). Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet vol. 48, (6) 700-700.
10.1038/ng0616-700b
Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ(2016). Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. British Journal of Clinical Pharmacology vol. 81, (5) 989-998.
10.1111/bcp.12878
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18499
Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S et al.(2016). Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica: the hematology journal vol. 101, (5) 531-540.
10.3324/haematol.2015.139493
Edelmann J, Gribben JG(2016). Obinutuzumab for the treatment of indolent lymphoma. Future Oncol vol. 12, (15) 1769-1781.
10.2217/fon-2016-0084
Kotsiou E, Okosun J, Besley C, Iqbal S, Matthews J, Fitzgibbon J, Gribben J, DAVIES JK(2016). TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood vol. 128, (1) 72-81.
10.1182/blood-2015-10-679191
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12275
Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, Hoster E, Kahl B et al. (2016). Minimal residual disease analysis in patients with follicular lymphoma treated with obinutuzumab plus bendamustine versus bendamustine alone in GADOLIN, a phase III study of relapsed/refractory indolent non-Hodgkin lymphoma. British Journal of Haematology, Supplement. Conference: XXXVI World Congress of the International Society of Hematology (Glasgow) from: 18/04/2016 to: 21/04/2016, vol. 173, 93-94.
Griessinger E, Anjos-Afonso F, Vargaftig J, Taussig DC, Lassailly F, Prebet T, Imbert V, Nebout M et al.(2016). Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer Res vol. 76, (8) 2082-2086.
10.1158/0008-5472.CAN-15-2063
Riches JC, Gribben JG(2016). Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia. Current Cancer Drug Targets vol. 16,
10.2174/1568009616666160408145741
Kotsiou E, Gribben JG, Davies JK(2016). Allospecific Tregs expanded after anergization remain suppressive in inflammatory conditions but lack expression of gut-homing molecules. Molecular therapy : the journal of the American Society of Gene Therapy vol. 24, (6) 1126-1134.
10.1038/mt.2016.64
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25657
Iyengar S, Ariza-Mcnaughton L, Clear A, Taussig D, Auer R, Roe A, Lillington D, Iqbal S et al.(2016). Characteristics of human primary mantle cell lymphoma engraftment in NSG mice. British Journal of Haematology vol. 173, (1) 165-169.
10.1111/bjh.13581
Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GAM, Michallet AS, Hillmen P, Dürig J et al.(2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: Data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal vol. 6,
10.1038/bcj.2016.9
Hanna BS, McClanahan F, Yazdanparast H, Zaborsky N, Kalter V, Rößner PM, Benner A, Dürr C et al.(2016). Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia vol. 30, (3) 570-579.
10.1038/leu.2015.305
Freeman CL, Gribben JG(2016). Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Current Hematologic Malignancy Reports vol. 11, (1) 29-36.
10.1007/s11899-015-0295-9
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al.(2016). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics vol. 48, (2) 183-188.
10.1038/ng.3473
Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J et al.(2016). Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant vol. 51, (2) 186-193.
10.1038/bmt.2015.221
Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, De Wit TD, Eichinger S et al.(2016). The european hematology association roadmap for european hematology research: A consensus document. Haematologica vol. 101, (2) 115-208.
10.3324/haematol.2015.136739
Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG et al.(2016). Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leukemia and Lymphoma vol. 57, (6) 1291-1299.
10.3109/10428194.2015.1128540
Okosun J, Wolfson RL, Wang J, Araf S, Wilkins L, Castellano BM, Escudero-Ibarz L, Al Seraihi AF et al. (2015). Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics.
10.1038/ng.3473
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M et al.(2015). Autologous hematopoetic stem cell transplantation for refractory Crohn disease a randomized clinical trial. JAMA - Journal of the American Medical Association vol. 314, (23) 2524-2534.
10.1001/jama.2015.16700
Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E et al.(2015). Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood vol. 126, (24) 2646-2649.
10.1182/blood-2015-09-670802
Pott C, Belada D, Danesi N, Fingerle-Rowson G, Gribben J, Harbron C, Hoster E, Kahl BS et al. (2015). Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. vol. 126, 3978-3978.
10.1182/blood.v126.23.3978.3978
Cui B, Chen L, Rassenti LZ, Ghia EM, Yu J, Zhang L, Neuberg DS, Wierda W et al. (2015). High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. Blood. vol. 126, 1713-1713.
10.1182/blood.v126.23.1713.1713
Norster F, Clear AJ, Matthews J, Hoxha E, Gribben J, Jia L (2015). Overexpression of HMGB1 Receptor RAGE Is Associated with Worse Clinical Outcome in Patients with Chronic Lymphocytic Leukemia. Blood. vol. 126, 617-617.
10.1182/blood.v126.23.617.617
Cheson BD, Trask PC, Gribben J, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner Fritsch E et al. (2015). Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma. Blood. vol. 126, 1532-1532.
10.1182/blood.v126.23.1532.1532
Flinn IW, Brunvand M, Choi MY, Dyer MJS, Gribben J, Hillmen P, Jones J, Li Y et al. (2015). Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). Blood. vol. 126, 494-494.
10.1182/blood.v126.23.494.494
Taylor JG, Gribben JG(2015). Microenvironment abnormalities and lymphomagenesis: Immunological aspects. Seminars in Cancer Biology vol. 34, 36-45.
10.1016/j.semcancer.2015.07.004
Tawana K, Wang J, Renneville A, Bödör C, Hills R, Loveday C, Savic A, Van Delft FW et al.(2015). Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood vol. 126, (10) 1214-1223.
10.1182/blood-2015-05-647172
Carlotti E, Wrench D, Rosignoli G, Marzec J, Sangaralingam A, Hazanov L, Michaeli M, Hallam S et al.(2015). High throughput sequencing analysis of the immunoglobulin heavy chain gene from flow-sorted B cell sub-populations define the dynamics of follicular lymphoma clonal evolution. PLoS ONE vol. 10, (9)
10.1371/journal.pone.0134833
Gribben JG, Fowler N, Morschhauser F(2015). Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol vol. 33, (25) 2803-2811.
10.1200/JCO.2014.59.5363
McClanahan F, Gribben J(2015). New insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective. Clin Adv Hematol Oncol vol. 13, (9) 586-594.
Munir T, Cohen D, Pocock C, Rawstron A, Collet L, McParland L, Chalmers A, Varghese A et al.(2015). Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials. LEUKEMIA & LYMPHOMA vol. 56, 26-27.
Ghazaly EA, Gnanaranjan C, Greenhalf B, Blagden SP, Mullen P, Harrison D, Gribben JG (2015). Abstract 3390: Validating the RNAscope for molecular profiling of key biomarkers associated with gemcitabine resistance. 3390-3390.
10.1158/1538-7445.am2015-3390
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M et al.(2015). Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model. Blood vol. 126, (2) 212-221.
10.1182/blood-2015-02-626754
McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, Seiffert M(2015). PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood vol. 126, (2) 203-211.
10.1182/blood-2015-01-622936
Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M et al.(2015). Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood vol. 125, (26) 4060-4068.
10.1182/blood-2014-10-608133
Wilkes EH, Terfve C, Gribben JG, Saez-Rodriguez J, Cutillas PR(2015). Empirical inference of circuitry and plasticity in a kinase signaling network. Proc Natl Acad Sci U S A vol. 112, (25) 7719-7724.
10.1073/pnas.1423344112
https://qmro.qmul.ac.uk/xmlui/handle/123456789/28857
Sehn LH, Chua NS, Mayer J, Dueck GS, Trneny M, Bouabdallah K, Fowler NH, Delwail V et al. (2015). GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Sehn LH, Chua NS, Mayer J, Dueck GS, Trn¿ný M, Bouabdallah K, Fowler NH, Delwail V et al.(2015). GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Journal of Clinical Oncology vol. 33, (18_suppl) lba8502-lba8502.
10.1200/jco.2015.33.18_suppl.lba8502
Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J et al.(2015). Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. International Journal of Cancer vol. 136, (12) 2761-2774.
10.1002/ijc.29326
Hassan S, Davies J, Smith M, Tsitsikas D, Oakervee H, Hallam S, Taussig D, Gribben J et al. (2015). DURABLE REMISSIONS AFTER SEQUENTIAL TRANSPLANTATION USING T-REPLETE NON-MYELOABLATIVE CONDITIONING FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA. HAEMATOLOGICA. vol. 100, 278-278.
Sehn L, Chua N, Mayer J, Dueck G, Trneny M, Bouabdallah K, Fowler N, Delwail V et al. (2015). GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA. HAEMATOLOGICA. vol. 100, 273-273.
Eyre T, Clifford R, Bloor A, Boyle L, Cabes M, Collins G, Devereux S, Follows G et al. (2015). SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME. HAEMATOLOGICA. vol. 100, 109-109.
Gribben JG(2015). XV. Clinical aspects of transformed lymphoma. Hematol Oncol vol. 33 Suppl 1, 80-83.
10.1002/hon.2223
Blagden SP, Rizzuto I, Stavraka C, O'Shea D, Suppiah P, Patel M, Loyse N, Sukumaran A et al. (2015). A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers. Journal of Clinical Oncology. vol. 33, 2547-2547.
10.1200/jco.2015.33.15_suppl.2547
https://qmro.qmul.ac.uk/xmlui/handle/123456789/8343
Leonard J, Gribben JG, Trnen M, Scheinberg P, Tobinai K, Fowler NH, Kilavuz N, Fustier P et al. (2015). AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R-2) versus placebo plus rituximab. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Blagden SP, Rizzuto I, Stavraka C, O'Shea D, Suppiah P, Patel M, Sukumaran A, Loyse N et al. (2015). Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies. Journal of Clinical Oncology. vol. 33, 2514-2514.
10.1200/jco.2015.33.15_suppl.2514
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12316
Sehn LH, Chua NS, Mayer J, Dueck GS, Trnen M, Bouabdallah K, Fowler NH, Delwail V et al. (2015). GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Flinn I, Moreno C, Gill DS, Kipps TJ, Shaw Y, Li Y, Styles LA, James DF et al. (2015). Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naive CLL/SLL (PCYC-1130): iLLUMINATE. JOURNAL OF CLINICAL ONCOLOGY. vol. 33,
Flinn I, Moreno C, Gill DS, Kipps TJ, Shaw Y, Li Y, Styles LA, James DF et al.(2015). Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC-1130): iLLUMINATE. Journal of Clinical Oncology vol. 33, (15_suppl) tps7095-tps7095.
10.1200/jco.2015.33.15_suppl.tps7095
Hanna B, McClanahan F, Zaborsky N, Duerr C, Kalter V, Egle A, Lichter P, Gribben J et al. (2015). Targeting dysfunctional myeloid cells delays disease development and improves immune function in a CLL mouse model. JOURNAL OF IMMUNOLOGY. vol. 194,
Taylor JG, Liapis K, Gribben JG(2015). The role of the tumor microenvironment in HIV-associated lymphomas. Biomarkers in Medicine vol. 9, (5) 473-482.
10.2217/bmm.15.13
Nakagawa R, Vukovic M, Tarafdar A, Cosimo E, Dunn K, McCaig AM, Holroyd A, McClanahan F et al.(2015). Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes. Haematologica vol. 100, (4) 499-510.
10.3324/haematol.2014.112276
Hondares E, Brown M, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D et al.(2015). Enhanced activation of an amino-terminally truncated isoform of voltage-gated proton channel HVCN1 enriched in malignant B cells. ACTA PHYSIOLOGICA vol. 213, 39-39.
Kotsiou E, Guinan E, Gribben J, Davies J (2015). Phenotypic and functional stability of regulatory T cells expanded after alloanergization with costimulatory molecule blockade. BONE MARROW TRANSPLANTATION. vol. 50, S373-S373.
Bento L, Boumendil A, Finel H, Chevallier P, Amorim S, Monjanel H, Blaise D, Bay J-O et al. (2015). Radioimmunotherapy and BEAM chemotherapy versus BEAM as the conditioning regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective matched-control study of the LWP-EBMT. BONE MARROW TRANSPLANTATION. vol. 50, S287-S288.
Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW et al.(2015). Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997. Leukemia and Lymphoma vol. 56, (11) 3031-3037.
10.3109/10428194.2015.1023800
Hondares E, Brown M, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D et al.(2015). Enhanced Activation of an Amino-Terminally Truncated Isoform of Voltage-Gated Proton Channel HVCN1 Enriched in Malignant B cells. Biophysical Journal vol. 108, (2)
10.1016/j.bpj.2014.11.133
Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F et al.(2015). Life expectancy of young adults with follicular lymphoma. Annals of Oncology vol. 26, (11) 2317-2322.
10.1093/annonc/mdv376
Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A et al.(2015). Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: Robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica vol. 100, (3) 363-369.
10.3324/haematol.2014.110189
Zhao T, Ren H, Wang X, Liu P, Yan F, Jiang W, Li Y, Li J et al.(2015). Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget vol. 6, (29) 27816-27831.
10.18632/oncotarget.4816
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12776
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M et al.(2014). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood vol. 124, (26) 3841-3849.
10.1182/blood-2014-07-586826
Hondares E, Brown MA, Musset B, Morgan D, Cherny VV, Taubert C, Bhamrah MK, Coe D et al.(2014). Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 111, (50) 18078-18083.
10.1073/pnas.1411390111
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6901
McClanahan F, Calore F, Zanesi N, Gribben JG, Croce CM (2014). Aberrant PD-L1 Expression in CLL As a Result of Adaptive Immune Resistance Mediated By Tumor-Secreted Circulating miRNA Binding to Toll-like Receptor 7. Blood. vol. 124, 716-716.
10.1182/blood.v124.21.716.716
Edelmann J, Saub J, Ibach S, Holzmann K, Tausch E, Bloehdorn J, Mertens D, Zenz T et al. (2014). High Resolution Genomic Profiling of Primary “Ultra High Risk” and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. Blood. vol. 124, 3288-3288.
10.1182/blood.v124.21.3288.3288
Hanna B, McClanahan F, Clear AJ, Miller S, Lichter P, Seiffert M, Gribben JG(2014). Immune Checkpoint Blockade with Anti-PD-L1 Prevents Immune Dysfuntion and CLL Development in the TCL1 Adoptive Transfer Mouse Model. Blood vol. 124, (21) 717-717.
10.1182/blood.v124.21.717.717
Sarker S-J, George GE, Chowdhury K, Levitt G, Kingston J, Lister A, Gribben JG, Korszun A(2014). Late Effects: An Evaluation of Contrasting Physical and Psychological Experiences Between Child and Adult Hodgkin Survivors. Blood vol. 124, (21) 1309-1309.
10.1182/blood.v124.21.1309.1309
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7549
Besley CM, Kotsiou E, Petty R, Sangaralingum A, Le Dieu R, Gribben JG, Davies JK (2014). Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile. Blood. vol. 124, 1103-1103.
10.1182/blood.v124.21.1103.1103
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7521
McCarthy A, Clear AJ, Marzec J, Coutinho R, Petty RD, Matthews J, Wilson A, Iqbal S et al. (2014). Overexpression of BCL-2 Does Not Inhibit Autophagy in Human Follicular and Diffuse Large B-Cell Lymphomas. Blood. vol. 124, 3007-3007.
10.1182/blood.v124.21.3007.3007
Ghazaly E, Smith P, Gnanaranjan C, Young BD, Joel S, Gribben JG, Taussig DC (2014). SKIP Is Underexpressed in AML Leading to Sphingosine Kinase Hypofunction. Blood. vol. 124, 5324-5324.
10.1182/blood.v124.21.5324.5324
Kotsiou E, Okosun J, Clear AJ, Iqbal S, Fitzgibbon J, Gribben JG, Davies JK (2014). TNFRSF14 aberrations in Follicular Lymphoma B Cells Result in Increased Alloresponses in Vitro and in Vivo. Blood. vol. 124, 2426-2426.
10.1182/blood.v124.21.2426.2426
Hanna B, McClanahan F, Zaborsky N, Dürr C, Kalter V, Egle A, Gribben JG, Lichter P et al.(2014). Targeting Dysfunctional Myeloid Cells Delays Disease Development and Improves Immune Function in a CLL Mouse Model. Blood vol. 124, (21) 3298-3298.
10.1182/blood.v124.21.3298.3298
Dürr C, Hanna B, McClanahan F, Clear AJ, Zenz T, Stilgenbauer S, Gribben JG, Lichter P et al. (2014). The Flavonoid Wogonin Reduces CLL Cell Survival in Vitro and Leukemia Development in Eµ-TCL1 Mice By Targeting Aberrant TNF Receptor Signaling. Blood. vol. 124, 1966-1966.
10.1182/blood.v124.21.1966.1966
McClanahan F, Gribben J(2014). Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?. Hematol Oncol Clin North Am vol. 28, (6) 1055-1071.
10.1016/j.hoc.2014.08.005
Ficz G, Gribben JG(2014). Loss of 5-hydroxymethylcytosine in cancer: cause or consequence?. Genomics vol. 104, (5) 352-357.
10.1016/j.ygeno.2014.08.017
El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M, Colombat P, Biron P et al.(2014). The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol vol. 25, (11) 2224-2229.
10.1093/annonc/mdu440
Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong P-P et al.(2014). Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature vol. 514, (7520) 112-116.
10.1038/nature13541
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6577
Ghazaly EA, Slusarczyk M, Mason M, Gribben J, McGuigan C, Blagden S (2014). Abstract CT401: NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival. ct401-ct401.
10.1158/1538-7445.am2014-ct401
JIA L(2014). Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. Oncotarget11653-11668.
10.18632/oncotarget.2605
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12767
Edelmann J, Haferlach C, Saub J, Teleanu V, Florence C, Leblonde V, Delmer A, Buehler A et al.(2014). Genomic characterization of primary ultra high-risk and refractory chronic lymphocytic leukemia: Results from the CLL2O trial. ONCOLOGY RESEARCH AND TREATMENT vol. 37, 220-220.
McClanahan F, Riches JC, Miller S, Ghazaly E, Day W, Capasso M, Gribben J(2014). PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide. ONCOLOGY RESEARCH AND TREATMENT vol. 37, 236-236.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6568
Greaves P, Lister TA, Gribben JG(2014). Parenthood in long-term survivors after CHOP with or without etoposide treatment for aggressive lymphoma - response to Meissner et al. Br J Haematol vol. 166, (4) 615-616.
10.1111/bjh.12874
Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC et al.(2014). Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood vol. 124, (1) 42-48.
10.1182/blood-2014-02-555722
Riches JC, Gribben JG(2014). Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. Semin Hematol vol. 51, (3) 228-234.
10.1053/j.seminhematol.2014.05.006
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al.(2014). Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. BLOOD vol. 123, (26) 4101-4110.
10.1182/blood-2014-01-552307
Gribben JG(2014). Immune responses and outcome in follicular lymphoma. J Clin Oncol vol. 32, (17) 1757-1759.
10.1200/JCO.2013.53.8439
Hanna B, McClanahan F, Zaborsky N, Duerr C, Gschwend V, Stilgenbauer S, Egle A, Gribben J et al. (2014). CLL INDUCES SEVERE SKEWING IN THE MYELOID COMPARTMENT IN PATIENTS AND IN THE TCL1 MOUSE MODEL. HAEMATOLOGICA. vol. 99, 228-229.
Munir T, Cohen D, Pocock C, Rawstron A, McParland L, Chalmers A, Varghese A, Smith A et al. (2014). ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS. HAEMATOLOGICA. vol. 99, 54-54.
Leonard J, Gribben JG, Trneny M, Scheinberg P, Kilavuz N, Patturajan M, Fustier P (2014). AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology. vol. 32, tps8614-tps8614.
10.1200/jco.2014.32.15_suppl.tps8614
Ghazaly EA, Luong P, Chmielewska-Kassassir M, Wozniak L, Bomalaski JS, Gribben JG, Szlosarek PW (2014). Metabolomic analysis of pegylated arginine deiminase treatment in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. vol. 32, 7587-7587.
10.1200/jco.2014.32.15_suppl.7587
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11295
Besley C, Kotsiou E, Petty R, Sangaralingam A, LeDieu R, Gribben J, Davies J (2014). Lenalidomide potentiates human T cell alloresponses by selectively increasing proliferation of alloreactive CD8+cells which exhibit a novel gene expression profile - implications for IMiD therapy after allogeneic haematopoietic stem cell transplant. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 16-17.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9504
Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, Wang J, Iqbal S et al. (2014). Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 16-16.
Hillmen P, Pettitt A, Schuh A, Milligan D, Bowles K, Bareford D, Riaz JM, Follows G et al. (2014). Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted). BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 19-20.
Bloor AJC, Cohen D, Pocock C, Rawstron A, McParland L, Chalmers A, Varghese A, Smith A et al. (2014). Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 18-18.
Riches JC, O'Donovan C, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Croce CM, Ramsay AG et al. (2014). Trisomy 12 chronic lymphocytic leukaemia cells exhibit functional upregulation of integrin signalling that is modulated by NOTCH1 mutations. BRITISH JOURNAL OF HAEMATOLOGY. vol. 165, 20-20.
10.1182/blood-2014-01-552307
Jia L, Gribben JG(2014). Dangerous power: mitochondria in CLL cells. Blood vol. 123, (17) 2596-2597.
10.1182/blood-2014-03-558965
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al.(2014). Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study. JOURNAL OF CLINICAL ONCOLOGY vol. 32, (12) 1236-+.
10.1200/JCO.2013.49.6547
Griessinger E, Anjos-Afonso F, Pizzitola I, Rouault-Pierre K, Vargaftig J, Taussig D, Gribben J, Lassailly F et al.(2014). A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl Med vol. 3, (4) 520-529.
10.5966/sctm.2013-0166
Renaudon-Smith E, Gribben JG, Agrawal SG(2014). Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone. Eur J Haematol vol. 92, (4) 360-361.
10.1111/ejh.12248
Sander B, de Jong D, Rosenwald A, Xie W, Balague O, Calaminici M, Carreras J, Gaulard P et al.(2014). The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. HAEMATOLOGICA vol. 99, (4) 715-725.
10.3324/haematol.2013.095257
Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, Wang J, Iqbal S et al.(2014). Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood vol. 123, (13) 2066-2074.
10.1182/blood-2012-12-469833
Jia L, Clear A, Liu F-T, Matthews J, Uddin N, McCarthy A, Hoxha E, Durance C et al.(2014). Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood vol. 123, (11) 1709-1719.
10.1182/blood-2013-10-529610
Besley C, Kotsiou E, Petty R, Sangaralingam A, LeDieu R, Gribben J, Davies J (2014). LENALIDOMIDE POTENTIATES HUMAN T CELL ALLORESPONSES BY SELECTIVELY INCREASING PROLIFERATION OF ALLOREACTIVE CD8+CELLS WHICH EXHIBIT A NOVEL GENE EXPRESSION PROFILE - IMPLICATIONS FOR IMID THERAPY AFTER ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANT. BONE MARROW TRANSPLANTATION. vol. 49, S310-S311.
Korszun A, Sarker S-J, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G et al.(2014). Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol vol. 164, (6) 790-803.
10.1111/bjh.12698
Hassan S, Matthews J, Guy A, Farrell M, Taussig D, Smith M, Oakervee H, Cavenagh J et al. (2014). REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA. BONE MARROW TRANSPLANTATION. vol. 49, S350-S351.
Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J et al. (2014). SECOND RIC ALLOGENEIC TRANSPLANT AS A RESCUE STRATEGY FOR ACUTE LEUKAEMIA PATIENTS WHO RELAPSE AFTER AN INITIAL RIC ALLOGENEIC TRANSPLANTATION: ANALYSIS OF RISK FACTORS AND TREATMENT OUTCOMES. BONE MARROW TRANSPLANTATION. vol. 49, S194-S195.
El-Najjar I, Montoto S, McDowell A, Matthews J, Gribben J, Szyszko TA(2014). The value of semiquantitative analysis in identifying diffuse bone marrow involvement in follicular lymphoma. Nuclear Medicine Communications vol. 35, (3) 311-315.
10.1097/MNM.0000000000000059
Liapis K, Taussig D, Cotter FE, Gribben JG(2014). Cutaneous cryptococcosis in Hodgkin lymphoma. Br J Haematol vol. 164, (4)
10.1111/bjh.12615
Greaves P, Sarker SJ, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A et al.(2014). Fertility and sexual function in long-term survivors of haematological malignancy: Using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. British Journal of Haematology vol. 164, (4) 526-535.
10.1111/bjh.12651
Greaves P, Sarker S-J, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A et al.(2014). Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol vol. 164, (4) 526-535.
10.1111/bjh.12651
Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, Boller S, Cittaro D et al.(2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics vol. 46, (2) 176-181.
10.1038/ng.2856
Okosun J, Bödör C, Wang J, Araf S, Yang C-Y, Pan C, Boller S, Cittaro D et al.(2014). Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet vol. 46, (2) 176-181.
10.1038/ng.2856
Burger JA, Gribben JG(2014). The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol vol. 24, 71-81.
10.1016/j.semcancer.2013.08.011
Riches JC, Gribben JG(2014). Hanging tough: CMV-specific CD8+ T cells in CLL. Blood vol. 123, (5) 608-609.
10.1182/blood-2013-12-540922
Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG et al.(2014). Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. Cancer Genet vol. 207, (1-2) 19-30.
10.1016/j.cancergen.2014.01.004
McCarthy A, Marzec J, Clear A, Petty RD, Coutinho R, Matthews J, Wilson A, Iqbal S et al.(2014). Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2. Oncotarget vol. 5, (22) 11653-11668.
10.18632/oncotarget.2605
Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, Alvarez R, Gomes da Silva M et al.(2013). Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res vol. 19, (24) 6686-6695.
10.1158/1078-0432.CCR-13-1482
Riches JC, Gribben JG(2013). Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia. Discov Med vol. 16, (90) 295-302.
Kotsiou E, Gribben J, Davies J (2013). Phenotypic and functional characterisation of alloantigen-specific regulatory T cells expanded after in vitro anergisation with co-stimulatory molecule blockade. IMMUNOLOGY. vol. 140, 22-22.
Miraki-Moud F, Ariza-McNaughton L, Ghazaly EA, Hodby KA, Luong P, Clear A, Sohrabi F, Bomalaski J et al. (2013). Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo. Blood. vol. 122, 1458-1458.
10.1182/blood.v122.21.1458.1458
Wrench D, Rizvi H, Wilson A, O'Riain C, Clear A, Matthews J, Laszlo D, Lister TA et al.(2013). Concurrent Follicular Lymphoma At Diagnosis Has a Negative Impact On The Outcome Of Patients With Diffuse Large B Cell Lymphoma. Blood vol. 122, (21) 4260-4260.
10.1182/blood.v122.21.4260.4260
Chen S-S, Herndon TM, Emson C, Riches JC, McClanahan F, Tong T, Yan X-J, Patten PEM et al. (2013). Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues. Blood. vol. 122, 115-115.
10.1182/blood.v122.21.115.115
Manodoro F, Marzec J, Wang J, Chaplin T, Jovanovic JV, Eva M, Sameena I, Grimwade D et al. (2013). Loss of Imprinting at the 14q32 Domain Leads to MicroRNA Overexpression in Acute Promyelocytic Leukemia. Blood. vol. 122, 2494-2494.
10.1182/blood.v122.21.2494.2494
Riches JC, Sangaralingam A, Chaplin T, McClanahan F, Iqbal S, Agrawal SG, Ramsay AG, Gribben J(2013). NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide. Blood vol. 122, (21) 4131-4131.
10.1182/blood.v122.21.4131.4131
Korszun A, Sarker S-J, Chowdhury K, Clark C, Greaves P, Johnson R, Kingston J, Levitt G et al. (2013). Psychosocial Factors and Impact Of Cancer In British Long-Term Haematological Cancer Survivors. Blood. vol. 122, 2943-2943.
10.1182/blood.v122.21.2943.2943
McClanahan F, Miller S, Riches JC, Ghazaly E, Day WP, Capasso M, Gribben J(2013). T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment. Blood vol. 122, (21) 4120-4120.
10.1182/blood.v122.21.4120.4120
O'Donovan CJ, Ramsay AG, McClanahan F, Rassenti L, Kipps TJ, Gribben J, Riches JC(2013). Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility. Blood vol. 122, (21) 4159-4159.
10.1182/blood.v122.21.4159.4159
Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z et al.(2013). HIF-2 alpha Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. CELL STEM CELL vol. 13, (5) 549-563.
10.1016/j.stem.2013.08.011
Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, Mitter R, Ivanovic Z et al.(2013). HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress. Cell Stem Cell vol. 13, (5) 549-563.
10.1016/j.stem.2013.08.011
Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J et al.(2013). Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology vol. 145, (5) 1121-1132.
10.1053/j.gastro.2013.07.025
Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S et al.(2013). EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood vol. 122, (18) 3165-3168.
10.1182/blood-2013-04-496893
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJN, Decker WK, Li S et al.(2013). Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS ONE vol. 8, (10)
10.1371/journal.pone.0076781
Greaves P, Clear A, Owen A, Iqbal S, Lee A, Matthews J, Wilson A, Calaminici M et al.(2013). Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood vol. 122, (16) 2856-2863.
10.1182/blood-2013-06-508044
Gribben JG(2013). B-cell receptor pathway inhibitors-rationale and potential. Clin Adv Hematol Oncol vol. 11 Suppl 12, (9) 3-4.
Gribben JG(2013). The sequence of events in diffuse large B-cell lymphoma. Blood vol. 122, (7) 1097-1098.
10.1182/blood-2013-06-506089
Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D, Jia L, Davies JK et al.(2013). Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proc Natl Acad Sci U S A vol. 110, (33) 13576-13581.
10.1073/pnas.1301891110
Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, Gribben JG(2013). Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion. Br J Haematol vol. 162, (4) 525-529.
10.1111/bjh.12402
Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, Calaminici M, Neuberg DS et al.(2013). Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol vol. 31, (21) 2654-2661.
10.1200/JCO.2012.44.2137
Liapis K, Clear A, Owen A, Coutinho R, Greaves P, Lee AM, Montoto S, Calaminici M et al.(2013). The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood vol. 122, (3) 424-433.
10.1182/blood-2013-03-488171
Greaves P, Wilson A, Matthews J, Gribben J (2013). A SIMPLE, ACCESSIBLE NEW TOOL TO DEFINE HIGH RISK PATIENTS IN CLASSICAL HODGKIN LYMPHOMA BASED ON VALIDATION OF PRE-EXISTING BIOMARKERS. HAEMATOLOGICA. vol. 98, 67-68.
Coutinho R, Flook M, Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A et al. (2013). HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA. HAEMATOLOGICA. vol. 98, 129-129.
Hillmen P, Pocock C, Rawstron A, McParland L, Chalmers A, Varghese A, Smith A, Collett C et al. (2013). RESULTS OF THE RANDOMISED PHASE II NCRI ADMIRE TRIAL OF FCR AND FCM-R IN PREVIOUSLY UNTREATED CLL: ORAL FCR IS HIGHLY EFFECTIVE AND SAFE BUT THE ADDITION OF MITOXANTRONE DOES NOT IMPROVE RESPONSES. HAEMATOLOGICA. vol. 98, 473-474.
Greaves P, Iqbal S, Wilson A, Matthews J, Calaminici M, Gribben J (2013). THE TH-INFILTRATE OF HODGKIN LYMPHOMA HAS A UNIQUE PHENOTYPE RICH IN ACTIVATION/PROLIFERATION MARKERS, CENTRAL MEMORY & TH1-POLARISED CELLS, WITHOUT EVIDENCE OF SENESCENCE, SUPPRESSION OR EXHAUSTION. HAEMATOLOGICA. vol. 98, 221-221.
Ghazaly EA, Joel S, Gribben JG, Mohammad T, Emiloju O, Stavraka C, Hopkins T, Gabra H et al. (2013). ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. vol. 31,
Marafioti T, Copie-Bergman C, Calaminici M, Paterson JC, Shende VH, Liu H, Baia M, Ramsay AD et al.(2013). Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. HISTOPATHOLOGY vol. 62, (6) 860-875.
10.1111/his.12076
Ramsay AG, Evans R, Kiaii S, Svensson L, Hogg N, Gribben JG(2013). Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood vol. 121, (14) 2704-2714.
10.1182/blood-2012-08-448332
Gribben J(2013). Bendamustine for non-Hodgkin lymphoma. Interview by Louise Rishton. Expert Rev Hematol vol. 6, (2) 123-125.
10.1586/ehm.13.13
Bento L, Anderson D, Davies J, Dark L, Gribben J, Montoto S (2013). Capping of body surface area is not necessary for dosing of high dose chemotherapy and autologous stem cell rescue in patients with body surface area > 2m2. BONE MARROW TRANSPLANTATION. vol. 48, S230-S231.
Burlinson ND, McCloskey D, Gribben J (2013). Clinical audit of HLA typing performed on adult patients not receiving an allograft at time of testing. BONE MARROW TRANSPLANTATION. vol. 48, S100-S101.
van Delft FW, Mansur MB, Furness C, Minto L, Irving J, Iqbal S, Noronha E, Colman S et al.(2013). Genetics of teenage and young adult t-cell acute lymphoblastic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY vol. 161, 12-12.
Julve M, Hassan S, Matthews J, Farrell M, Guy A, Popat R, Smith M, Oakervee H et al. (2013). Multiple myeloma: a comparison of two melphalan conditioning regimens (200 mg/m2 versus 140 mg/m2) for autologous stem cell transplantation. BONE MARROW TRANSPLANTATION. vol. 48, S226-S227.
Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG, Lister TA(2013). Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica vol. 98, (4) 620-625.
10.3324/haematol.2012.069583
Greaves P, Sarker S, Chowdhury K, Johnson R, Matthews J, Matthews R, Smith M, Korszun A et al.(2013). Self-reported sexual functioning and fertility in long survivors of haematological malignancy: a neglected area of need in the late-effects clinic. BRITISH JOURNAL OF HAEMATOLOGY vol. 161, 55-55.
Okosun J, Clear A, Iqbal S, Matthews J, Gribben J, Fitzgibbon J, Davies J (2013). TNFRSF14 aberrations are associated with death from acute GvHD after reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation for follicular lymphoma. BONE MARROW TRANSPLANTATION. vol. 48, S169-S169.
Riches JC, Gribben JG(2013). Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. Hematol Oncol Clin North Am vol. 27, (2) 207-235.
10.1016/j.hoc.2013.01.003
Iyengar S, Clear A, Bödör C, Maharaj L, Lee A, Calaminici M, Matthews J, Iqbal S et al.(2013). P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood vol. 121, (12) 2274-2284.
10.1182/blood-2012-10-460832
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P et al.(2013). ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol vol. 24, (3) 561-576.
10.1093/annonc/mds517
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG(2013). T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood vol. 121, (9) 1612-1621.
10.1182/blood-2012-09-457531
Gribben J, Coutinho(2013). Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. Current Biomarker Findings vol. Volume 3, 17-34.
10.2147/cbf.s29208
Brown JR, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J, Ritz J et al.(2013). Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia vol. 27, (2) 362-369.
10.1038/leu.2012.228
Greaves P, Gribben JG(2013). The role of B7 family molecules in hematologic malignancy. Blood vol. 121, (5) 734-744.
10.1182/blood-2012-10-385591
Greaves P, Gribben JG(2013). A shot in the arm for radiotherapy. Blood vol. 121, (2) 246-248.
10.1182/blood-2012-11-465526
Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A, Shanyinde M, Lister TA et al.(2013). Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol vol. 31, (2) 256-262.
10.1200/JCO.2011.39.9881
Vallat L, Kemper CA, Jung N, Maumy-Bertrand M, Bertrand F, Meyer N, Pocheville A, III FJW et al.(2013). Reverse-engineering the genetic circuitry of a cancer cell with predicted intervention in chronic lymphocytic leukemia. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA vol. 110, (2) 459-464.
10.1073/pnas.1211130110
Gribben JG, Riches JC(2013). Immunotherapeutic strategies including transplantation: eradication of disease. Hematology Am Soc Hematol Educ Program vol. 2013, 151-157.
10.1182/asheducation-2013.1.151
Greaves P, Gribben JG(2012). Lymphoid neoplasia. Laser-capturing the essence of Hodgkin lymphoma. Blood vol. 120, (23) 4451-4452.
10.1182/blood-2012-09-455873
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.(2012). HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol vol. 30, (33) 4111-4116.
10.1200/JCO.2011.41.4193
Butler T, Montoya A, Clear AJ, Coutinho R, Taussig DC, Cutillas P, Gribben JG (2012). Anergic Response to B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: The Differing Roles of IgD and IgM in the Microenvironment and Peripheral Blood. BLOOD. vol. 120,
10.1182/blood.V120.21.2889.2889
El Najjar I, Szyszko T, Mc Dowell A, Matthews J, Gribben JG, Montoto S (2012). Assessment of Bone Marrow Involvement by FDG-PET in Patients with Follicular Lymphoma. BLOOD. vol. 120,
10.1182/blood.v120.21.5108.5108
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG(2012). Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide. Blood vol. 120, (21) 564-564.
10.1182/blood.v120.21.564.564
Van Delft FW, Furness CL, Mansur MB, Minto L, Irving J, Iqbal S, Noronha E, Colman S et al.(2012). Genetics of Teenage and Young Adult Acute Lymphoblastic T-Cell Leukaemia. Blood vol. 120, (21) 2521-2521.
10.1182/blood.v120.21.2521.2521
Al-Malti A, Gribben JG, Jia L(2012). HMGB1 Activates TLR9/RAGE Signalling Pathway and Sustains Chronic Lymphocytic Leukemic Cell in Vitro Survival. Blood vol. 120, (21) 3860-3860.
10.1182/blood.v120.21.3860.3860
Bo¿odo¿or C, Vera G, Kohlmann A, Tan K, Okosun J, Popov N, Araf S, Marzec J et al.(2012). High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood vol. 120, (21) 545-545.
10.1182/blood.v120.21.545.545
Iyengar S, Ariza-McNaughton L, Clear AJ, Roe A, Lillington D, Taussig DC, Gribben JG, Joel S et al. (2012). Human Primary Mantle Cell Lymphoma Can Be Established in NOD/SCID/IL2R gamma-Null Mice. BLOOD. vol. 120,
10.1182/blood.V120.21.1565.1565
Maharaj L, Popat R, Gribben JG, Joel S (2012). IL-6, IL-8 and VEGF Neutralisation Restores Drug Sensitivity to Conventional and Novel Treatment Combinations in a Multiple Myeloma Bone Marrow Micro-Environment Model. BLOOD. vol. 120,
10.1182/blood.V120.21.2949.2949
Kiaii S, Clear AJ, Gribben JG (2012). Impact of Tumor Infiltrating T Cells in Patients with Diffuse Large B-Cell Lymphoma. BLOOD. vol. 120,
10.1182/blood.V120.21.1572.1572
Iyengar S, Clear AJ, Boedor C, Maharaj L, Matthews J, Auer R, Iqbal S, Gribben JG et al. (2012). Increased Tonic PI3K Signaling Through p110 alpha Can Limit the Efficacy of P110 delta -Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse. BLOOD. vol. 120,
10.1182/blood.V120.21.1652.1652
McCarthy A, Yeung V, Gribben JG, Jia L (2012). Inhibition of Autophagy by Chloroquine Sensitises Lymphoma Cells to ABT-737-Induced Apoptosis. BLOOD. vol. 120,
10.1182/blood.V120.21.1625.1625
McClanahan F, Ghirelli C, Greaves P, Riches JC, Coutinho R, Ramsay AG, Gribben JG (2012). Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On E mu-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo. BLOOD. vol. 120,
10.1182/blood.V120.21.313.313
El-Najjar I, Matthews J, Wilson A, Gribben JG, Montoto S (2012). The Clinical Course of Patients with Follicular Lymphoma in the Rituximab Era: A Paradigm Shift. BLOOD. vol. 120,
10.1182/blood.V120.21.1580.1580
Coutinho R, Newman AM, Rossignoli G, Day W, Miraki-Moud F, Chaplin T, Marzec J, Petty RD et al. (2012). The Diffuse Large B-Cell Lymphoma Infiltrating Macrophage Transcriptome Signature Is Enriched for Both M1 and M2 Genes and Provides an Excellent Platform for Functional Validation of Macrophage Biology in DLBCL. BLOOD. vol. 120,
10.1182/blood.V120.21.790.790
Korszun A, Johnson R, Sarker S-J, Kashfia C, Clark C, Greaves P, Kingston J, Levitt G et al.(2012). The Relationship of Depression and Anxiety and Impact of Cancer in Long-Term Survivors of Haematological Malignancy. Blood vol. 120, (21) 3174-3174.
10.1182/blood.v120.21.3174.3174
Okosun J, Boedoer C, Wang J, Araf S, Marzec J, Iqbal S, Matthews J, Calaminici M et al. (2012). Whole Genome Sequencing in Sequential Biopsies Reveals the Genetic Evolution of Follicular Lymphoma to Transformed Follicular Lymphoma. BLOOD. vol. 120,
10.1182/blood.V120.21.145.145
McClanahan F, Gribben JG(2012). Immunotherapeutic Approaches Have the Potential to Brighten the Future Not Only for Patients With del(17p13.1), but for All CLL Patients THE STEPHENS/BYRD ARTICLE REVIEWED. ONCOLOGY-NEW YORK vol. 26, (11) 1055-+.
McClanahan F, Gribben JG(2012). Immunotherapeutic approaches have the potential to brighten the future not only for patients with del(17p13.1), but for all CLL patients. Oncology (Williston Park) vol. 26, (11) 1055-1058.
Nagler A, Labopin M, Shimoni A, Mufti GJ, Cornelissen JJ, Blaise D, Janssen JJWM, Milpied N et al.(2012). Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. EUROPEAN JOURNAL OF HAEMATOLOGY vol. 89, (3) 206-213.
10.1111/j.1600-0609.2012.01811.x
Lozanski G, Ruppert AS, Heerema NA, Lozanski A, Lucas DM, Gordon A, Gribben JG, Morrison VA et al.(2012). Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. LEUKEMIA & LYMPHOMA vol. 53, (9) 1743-1748.
10.3109/10428194.2012.668683
Ramsay AG, Clear AJ, Fatah R, Gribben JG(2012). Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood vol. 120, (7) 1412-1421.
10.1182/blood-2012-02-411678
Riches JC, Gribben JG(2012). Less expensive CARs?. Cytotherapy vol. 14, (7) 773-774.
10.3109/14653249.2012.698119
El-Najjar I, Szyszko T, Mc Dowell A, Matthews J, Gribben J, Montoto S (2012). ASSESSMENT OF BONE MARROW INVOLVEMENT BY FDG-PET/CT IN PATIENTS WITH FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 97, 664-664.
Liu F, Jia L, Farren T, Gribben J, Agrawal S (2012). AUTOCRINE IL-6 PRODUCTION CORRELATED WITH SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS. HAEMATOLOGICA. vol. 97, 517-517.
Greaves P, Iqbal S, Rosignoli G, Matthews J, Wilson A, Taussig D, Gribben J (2012). DOMINANCE OF NAIVE AND CENTRAL MEMORY CD4+T CELLS IN THE CLASSICAL HODGKIN LYMPHOMA MICROENVIRONMENT PROVIDES A DISTINCTIVE SIGNATURE WITH IMPLICATIONS FOR PATHOGENESIS AND CLINICAL DIAGNOSIS. HAEMATOLOGICA. vol. 97, 81-81.
Riches J, Davies J, McClanahan F, Iqbal S, Fatah R, Agrawal S, Ramsay A, Gribben J (2012). IDENTIFICATION OF AN EXPANDED POPULATION OF TERMINALLY DIFFERENTIATED CD8+T CELLS WITH A NOVEL PHENOTYPIC AND FUNCTIONAL PROFILE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA. vol. 97, 451-451.
Hassan S, Montoto S, Gribben J, De Vos J (2012). LOW-DOSE ETOPOSIDE AND CYTARABINE: A PALLIATIVE TREATMENT OPTION IN PATIENTS WITH REFRACTORY/RELAPSED DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR INTENSIVE SALVAGE CHEMOTHERAPY. HAEMATOLOGICA. vol. 97, 654-654.
Ramsay G, Clear A, Fatah R, Gribben J (2012). MULTIPLE INHIBITORY LIGANDS INDUCE T CELL IMMUNOLOGICAL SYNAPSE DYSFUNCTION IN HEMATOLOGIC MALIGNANCY THAT CAN BE BLOCKED WITH LENALIDOMIDE - DEFINING A REVERSIBLE IMMUNE EVASION MECHANISM IN CANCER. HAEMATOLOGICA. vol. 97, 230-230.
Butler T, Taussig D, Cutillas P, Gribben J (2012). PHOSPHOPROTEOMIC ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND B-CELL RECEPTOR SIGNALING SUGGESTS NOVEL THERAPEUTIC TARGETS. HAEMATOLOGICA. vol. 97, 49-49.
Greaves P, Clear A, Owen A, Wilson A, Matthews J, Calaminici M, Gribben J (2012). THE MICROENVIRONMENT IN CLASSICAL HODGKIN LYMPHOMA SHOWS EVIDENCE OF A TH1 AND NOT TH2 RESPONSE WITH TBET EXPRESSION BEING ASSOCIATED WITH IMPROVED SURVIVAL AND EBV STATUS. HAEMATOLOGICA. vol. 97, 455-455.
Patel S, Cavenagh J, Gribben J, De Vos J (2012). USE OR RITUXIMAB IN ACUTE AND CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) POST ALLOGENEIC HEMATOPOIETIC CELL-TRANSPLANTATION. HAEMATOLOGICA. vol. 97, 726-727.
Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A et al.(2012). Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol vol. 30, (20) 2483-2491.
10.1200/JCO.2011.39.3090
Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A et al.(2012). Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis vol. 3,
10.1038/cddis.2012.83
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B et al.(2012). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. LEUKEMIA vol. 26, (7) 1458-1461.
10.1038/leu.2012.25
Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, Agrawal S, Cavenagh JD et al.(2012). T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. Br J Haematol vol. 157, (5) 580-585.
10.1111/j.1365-2141.2012.09106.x
Zenz T, Gribben JG, Hallek M, Doehner H, Keating MJ, Stilgenbauer S(2012). Risk categories and refractory CLL in the era of chemoimmunotherapy. BLOOD vol. 119, (18) 4101-4107.
10.1182/blood-2011-11-312421
Joshi NM, Hassan S, Jasani P, Dixon S, Cavenagh JD, Oakervee HE, Smith M, Agrawal SA et al.(2012). Bile acid malabsorption in patients with graft-versus-host disease of the gastrointestinal tract. Br J Haematol vol. 157, (3) 403-407.
10.1111/j.1365-2141.2011.09014.x
White RE, Raemer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R et al.(2012). EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. JOURNAL OF CLINICAL INVESTIGATION vol. 122, (4) 1487-1502.
10.1172/JCI58092
Greaves P, Wilson A, Matthews J, Brown DLP, Auer R, Montoto S, Lister TA, Gribben JG(2012). Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: a single centre intention-to-treat analysis. Br J Haematol vol. 157, (2) 201-204.
10.1111/j.1365-2141.2011.08993.x
Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J, Oakervee H, Gribben J et al.(2012). Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia vol. 26, (4) 858-860.
10.1038/leu.2011.250
Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al.(2012). HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. HIV MEDICINE vol. 13, 5-5.
Wrench D, Matthews J, Montoto S, Gribben JG, Lister TA (2012). Management without radiotherapy may be an acceptable approach for stage 1 follicular lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. vol. 157, 52-52.
El-Najjar I, Boumendil A, Luan J, Thieblemont C, Blaise D, Thomson K, Mohty M, Colombat P et al. (2012). The outcome of patients with follicular lymphoma in the rituximab era treated with autologous stem cell transplant according to the high-dose regimen received. A retrospective study of the EBMT Lymphoma Working Party. BONE MARROW TRANSPLANTATION. vol. 47, S3-S4.
Jasani PD, MacDougall F, Smith MLW, Cavenagh JD, Lister TA, Gribben JG, Taussig DC, Oakervee HE (2012). Treatment of acute myeloid leukaemia in the elderly: a retrospective analysis. BRITISH JOURNAL OF HAEMATOLOGY. vol. 157, 64-65.
Wendtner C-M, Hillmen P, Mahadevan D, Buehler A, Uharek L, Coutre S, Frankfurt O, Bloor A et al.(2012). Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA vol. 53, (3) 417-423.
10.3109/10428194.2011.618232
Riches JC, Ramsay AG, Gribben JG(2012). Immune reconstitution in chronic lymphocytic leukemia. Curr Hematol Malig Rep vol. 7, (1) 13-20.
10.1007/s11899-011-0106-x
JIA L, Gopinathan G, Sukumar JT, Gribben JG(2012). Blocking Autophagy Prevents Bortezomib-Induced NF-kappaB Activation by Reducing I-kappaBalpha Degradation in Lymphoma Cells. PLoS One vol. 7, (2) Article e32584,
10.1371/journal.pone.0032584
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12768
DAVIES JK, Gribben JG(2012). Blockade of chemotaxis in graft-versus-host disease. New England Journal of Medicine vol. 367, (17)
10.1056/NEJMc1209665
Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S et al.(2012). Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One vol. 7, (12)
10.1371/journal.pone.0051390
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5370
Riches JC, Ramsay AG, Gribben JG(2012). Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy. Curr Pharm Des vol. 18, (23) 3389-3398.
10.2174/138161212801227023
Gribben JG(2012). Transplant in chronic lymphocytic leukemia: to do it or not and if so, when and how?. Am Soc Clin Oncol Educ Book399-404.
10.14694/EdBook_AM.2012.32.224
Jia L, Uddin N, Gribben JG (2011). Activation of Mitochondrial STAT3 Increases Mitochondrial Respiration and Inhibits Oxidative Stress in Chronic Lymphocytic Leukemic Cells. BLOOD. vol. 118, 133-133.
Liu F, Jia L, Farren TW, Gribben JG, Agrawal SG (2011). Autocrine IL-6 Production Indicates the Level of Activated STAT3 and NF-Kb of Chronic Lymphocytic Leukemia Cells. BLOOD. vol. 118, 778-778.
Xing D, Ramsay AG, Decker W, Lee DA, Robinson S, Shah N, Parmar S, Bollard CM et al. (2011). CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. BLOOD. vol. 118, 112-112.
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG(2011). Chronic Lymphocytic Leukemia Cells Co-Opt CD200, CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse. Blood vol. 118, (21) 802-802.
10.1182/blood.v118.21.802.802
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG (2011). Chronic Lymphocytic Leukemia Cells Co-Opt CD200,.CD270, CD274 and CD276 to Induce Impaired Actin Polarization At the T Cell Immune Synapse. BLOOD. vol. 118, 364-365.
Taussig DC, Gribben JG (2011). Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy. BLOOD. vol. 118, 1556-1557.
Greaves P, Iqbal S, Taussig DC, Gribben JG(2011). Continuous CD4+ T Cell Lines Derived From the Classical Hodgkin Lymphoma Microenvironment: A Challenge to the Assumption of Anergy,. Blood vol. 118, (21) 3645-3645.
10.1182/blood.v118.21.3645.3645
Coutinho R, Clear AJ, Owen DA, Greaves P, Hallam SL, Wilson A, Matthews J, Calaminici M et al. (2011). Exploring the Immune Microenvironment of Diffuse Large B Cell Lymphoma in a Tissue Microarray: Predicting Survival with a Score That Incorporates Macrophages, Cytotoxic and Regulatory T Cells. BLOOD. vol. 118, 434-435.
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. (2011). HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. BLOOD. vol. 118, 1557-1557.
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.(2011). HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era,. Blood vol. 118, (21) 3646-3646.
10.1182/blood.v118.21.3646.3646
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Cekdemir D, Iqbal S, Ramsay AG, Gribben JG (2011). Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD. vol. 118, 446-446.
Kiaii S, Clear AJ, Sangaralingam A, Gribben JG (2011). Impact of Tumor Infiltrating T Cells in Patients with Follicular Lymphoma At Diagnosis. BLOOD. vol. 118, 349-349.
Xing D, Ramsay AG, Robinson S, Bollard CM, Shah N, Champlin R, Gribben JG, Shpall EJ (2011). Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. BLOOD. vol. 118, 783-783.
Hallam SL, Candido J, Coutinho R, Maniati E, Thompson RG, van Rooijen N, Hagemann T, Gribben JG (2011). Manipulating Tumor Associated Macrophages (TAM) in a Mouse Model of B-Cell Non-Hodgkin Lymphoma (NHL). BLOOD. vol. 118, 720-720.
El-Najjar I, Matthews J, Gribben J, Montoto S (2011). Neither the FLIPI Nor the FLIPI2 Accurately Segregates Low- Risk From Intermediate- Risk Follicular Lymphoma Patients in Terms of Progression-Free Survival. BLOOD. vol. 118, 1144-1144.
Iyengar S, Clear AJ, Owen A, Maharaj L, Matthews J, Calaminici M, Auer R, Ghazaly E et al. (2011). PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110 delta-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients. BLOOD. vol. 118, 719-719.
Iyengar S, Clear AJ, Owen A, Maharaj L, Matthews J, Calaminici M, Auer R, Ghazaly E et al.(2011). PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients. Blood vol. 118, (21) 1654-1654.
10.1182/blood.v118.21.1654.1654
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG(2011). T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus. Blood vol. 118, (21) 1780-1780.
10.1182/blood.v118.21.1780.1780
Greaves P, Clear AJ, Owen A, Wilson A, Matthews J, Calaminici M, Gribben JG (2011). The PD1/PD-L1 Axis in the Classical Hodgkin Lymphoma Microenvironment: PD-1 Is Rarely Expressed but Identifies Patients with High-Risk Disease. BLOOD. vol. 118, 678-678.
El-Najjar I, Boumendil A, Luan JJ, Thieblemont C, Blaise D, Thomson K, Le Gouill S, Lissandre S et al. (2011). The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. BLOOD. vol. 118, 234-235.
Ramsay AG, Gribben JG(2011). The kiss of death in FL. Blood vol. 118, (20) 5365-5366.
10.1182/blood-2011-09-377283
Jia L, Uddin N, Gribben JG(2011). 2.17 Activation of STAT3 Increases Mitochondrial Respiration and Protects Mitochondria from Oxidative Damage in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia vol. 11, s170-s171.
10.1016/j.clml.2011.09.050
Liu F, Jia L, Farren T, Gribben J, Agrawal S(2011). 2.21 Autocrine Interleukin-6 Production Correlated with Survival of Chronic Lymphocytic Leukaemia Cells. Clinical Lymphoma Myeloma & Leukemia vol. 11,
10.1016/j.clml.2011.09.054
Liu F, Jia L, Farren T, Gribben J, Agrawal S(2011). 2.46 Signal Transducer and Activator of Transcription 3 and Nuclear Factor κB Activation Regulate Autocrine Interleukin-6 Production and Indicate the Prognosis of CLL. Clinical Lymphoma Myeloma & Leukemia vol. 11, s188-s189.
10.1016/j.clml.2011.09.079
Riches JC, Ramsay AG, Gribben JG(2011). Chronic lymphocytic leukemia: an update on biology and treatment. Curr Oncol Rep vol. 13, (5) 379-385.
10.1007/s11912-011-0188-6
Farren TW, Giustiniani J, Liu F-T, Tsitsikas DA, Macey MG, Cavenagh JD, Oakervee HE, Taussig D et al.(2011). Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood vol. 118, (8) 2174-2183.
10.1182/blood-2011-02-334326
Perrot A, Pionneau C, Nadaud S, Davi F, Leblond V, Jacob F, Merle-Beral H, Herbrecht R et al.(2011). A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. BLOOD vol. 118, (4) E1-E15.
10.1182/blood-2011-02-335125
Gribben JG(2011). Are Prognostic Factors in CLL Overrated? THE MOUGALIAN/O'BRIEN ARTICLE REVIEWED. ONCOLOGY-NY vol. 25, (8) 703-706.
Gribben JG(2011). Are prognostic factors in CLL overrated?. Oncology (Williston Park) vol. 25, (8) 703-706.
Montserrat E, Gribben JG(2011). Autografting CLL: the game is over!. Blood vol. 117, (23) 6057-6058.
10.1182/blood-2011-04-344093
Kiaii S, Clear AJ, Davis D, Ramsay AG, Sangaralingam A, Gribben JG (2011). DEFECTS AND ABNORMALITIES IN INFILTRATING T CELLS IN PATIENTS WITH FOLLICULAR LYMPHOMA AT DIAGNOSIS. ANNALS OF ONCOLOGY. vol. 22, 84-84.
Gribben J (2011). NEW EVIDENCE FOR MECHANISM OF ACTION OF IMIDS (R) IN LYMPHOMAS, FOCUS ON MCL. ANNALS OF ONCOLOGY. vol. 22, 254-255.
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. (2011). RITUXIMAB PLUS CHLORAMBUCIL (R-CHLORAMBUCIL) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): FINAL ANALYSIS OF AN OPEN-LABEL PHASE II STUDY. ANNALS OF ONCOLOGY. vol. 22, 123-123.
10.1200/JCO.2013.49.6547
Montoto S, Matthews J, Anderson D, Lister A, Gribben J (2011). THE NUMBER OF PREVIOUS TREATMENT LINES HAS NO IMPACT ON THE OUTCOME AFTER HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL RESCUE WITH BEAM FOR RELAPSED FOLLICULAR LYMPHOMA. ANNALS OF ONCOLOGY. vol. 22, 115-115.
Greaves P, Clear A, Owen A, Matthews J, Macdougall F, Wilson A, Lister A, Calaminici M et al. (2011). TOTAL NUMBER OF B CELLS, BUT NOT T CELLS AT DIAGNOSIS IN THE CLASSICAL HODGKIN LYMPHOMA MICROENVIRONMENT IS PREDICTIVE OF SURVIVAL. ANNALS OF ONCOLOGY. vol. 22, 153-153.
Montoto S, Matthews J, Anderson D, Lister TA, Gribben JG(2011). Outcome after high-dose therapy with autologous stem cell rescue with BEAM for relapsed follicular lymphoma. J Clin Oncol vol. 29, (15_suppl)
10.1200/jco.2011.29.15_suppl.e18512
Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA et al.(2011). Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol vol. 29, (10) 1349-1355.
10.1200/JCO.2010.31.1811
Bödör C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H, Calaminici M, Clear A et al.(2011). EZH2 Y641 mutations in follicular lymphoma. Leukemia vol. 25, (4) 726-729.
10.1038/leu.2010.311
El-Najjar I, Szyszko T, Matthews J, Gribben J, Avril N, Montoto S (2011). FDG-PET/CT staging in follicular lymphoma: effect on FLIPI score. BRITISH JOURNAL OF HAEMATOLOGY. vol. 153, 48-48.
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. (2011). Final response assessment of the CLL208 trial: an open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL). BRITISH JOURNAL OF HAEMATOLOGY. vol. 153, 21-21.
Johnson R, Greaves P, Powell M, Vinnicombe S, Wilson A, Sarker S, Gribben J, Lister A (2011). Survey of breast screening in long-term survivors treated with supra-diaphragmatic irradiation for lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. vol. 153, 47-47.
Wrench D, Leighton P, Skibola CF, Conde L, Cazier J-B, Matthews J, Iqbal S, Carlotti E et al.(2011). SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood vol. 117, (11) 3147-3150.
10.1182/blood-2010-10-315382
Greaves PJ, Gribben JG(2011). Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma. J Clin Oncol vol. 29, (8) 952-953.
10.1200/JCO.2010.33.2437
Gribben JG, O'Brien S(2011). Update on therapy of chronic lymphocytic leukemia. J Clin Oncol vol. 29, (5) 544-550.
10.1200/JCO.2010.32.3865
Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW et al.(2011). Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia. CANCER-AM CANCER SOC vol. 117, (1) 116-124.
10.1002/cncr.25379
Gribben JG, Hosing C, Maloney DG(2011). Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant vol. 17, (1 Suppl) S63-S70.
10.1016/j.bbmt.2010.10.011
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG (2011). T-cells from Patients With CLL Exhibit Phenotypic and Transcription Factor Profiles Of Exhaustion Independent of CMV Serostatus. Blood. vol. 118, 1780-1783.
Riches JC, Ramsay AG, Gribben JG(2010). T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol vol. 20, (6) 431-438.
10.1016/j.semcancer.2010.09.006
Hallam S, Gribben JG(2010). The Role of Stem‐Cell Transplantation in Chronic Lymphocytic Leukemia. Leukemias: Principles and Practice of Therapy,
Tsitsikas DA, Sibony DW, Oakervee HE, Agrawal SG, Smith M, Taussig DC, de Vos J, Stewart E et al. (2010). A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High Risk MDS and Other High Risk Myeoid Malignancies An Interim Report. BLOOD. vol. 116, 1430-1430.
Tsitsikas DA, Warcel-Sibony D, Oakervee HE, Agrawal SG, Smith M, Taussig DC, de Vos J, Stewart E et al. (2010). A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report. BLOOD. vol. 116, 1430-1430.
Tsitsikas DA, Warcel-Sibony D, Oakervee HE, Agrawal SG, Smith M, Taussig DC, de Vos J, Stewart E et al.(2010). A Phase II Trial of Sequential Treatment with Cytoreductive Therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukaemia, High-Risk MDS and Other High Risk Myeoid Malignancies: An Interim Report. Blood vol. 116, (21) 3480-3480.
10.1182/blood.v116.21.3480.3480
Greaves P, Wilson A, Matthews J, Brown DLP, Montoto S, Gribben JG, Lister A (2010). A Single-Centre Analysis by Intention to Treat with High Dose Chemotherapy and Autologous Stem Cell Rescue Following Second-Line Treatment In Patients with Hodgkin Lymphoma. BLOOD. vol. 116, 989-990.
Greaves P, Clear AJ, Owen DA, Macdougall F, Wilson A, Lister A, Calaminici M, Gribben JG (2010). An Immunohistochemical Score Based On CD68 and FOXP3 Expression In the Tumour Microenvironment at Diagnosis Defines Prognostic Groups In Both Early and Advanced Stage Classical Hodgkin Lymphoma. BLOOD. vol. 116, 330-330.
Liu F, Jia L, Farren T, Gribben JG, Agrawal S (2010). Autocrine IL6/STAT3 Signaling Enhances Survival of Chronic Lymphocytic Leukaemia Cells. BLOOD. vol. 116, 1481-1481.
Ramsay AG, Evans R, Svensson L, Kiati S, Hogg N, Gribben JG (2010). Defective LFA 1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway. BLOOD. vol. 116, 403-403.
Ramsay AG, Evans R, Svensson L, Kiaii S, Hogg N, Gribben JG (2010). Defective LFA-1 Mediated T Cell Motility In Chronic Lymphocytic Leukemia Is Mediated by Defects In the Rho GTPase Signaling Pathway. BLOOD. vol. 116, 403-403.
Kiaii S, Clear AJ, Ramsay AG, Sangaralingam A, Gribben JG (2010). Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients With Follicular Lymphoma at Diagnosis. BLOOD. Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) (Orlando, FL) from: 04/12/2010 to: 07/12/2010, vol. 116, 66-67.
Kiaii S, Clear AJ, Ramsay AG, Sangaralingam A, Gribben JG (2010). Differential Gene Expression Profile Identifies Defects and Abnormalities In Infiltrating T Cells In Patients with Follicular Lymphoma at Diagnosis. BLOOD. vol. 116, 66-67.
Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankturt O, Bloor A et al. (2010). Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL 001 Study). BLOOD. vol. 116, 591-592.
Wendtner C, Hillmen P, Mahadevan D, Stilgenbauer S, Uharek L, Coutre S, Frankfurt O, Bloor A et al. (2010). Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). BLOOD. vol. 116, 591-592.
10.1182/blood.v116.21.1376.1376
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG (2010). Functional Screening Studies Identify Combinational Activity of PD L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia. BLOOD. Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) (Orlando, FL) from: 04/12/2010 to: 07/12/2010, vol. 116, 306-307.
Ramsay AG, Clear AJ, Davenport A, Fatah R, Gribben JG (2010). Functional Screening Studies Identify Combinational Activity of PD-L1 and CD200 In Mediating Dysfunctional T Cell Immunological Synapse Formation In Chronic Lymphocytic Leukemia. BLOOD. vol. 116, 306-307.
Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR et al. (2010). Increased Incidence of Therapy Related Myeloid Neoplasia (t MN) After Initial Therapy for CLL with Fludarabine Cyclophosphamide (FC) Vs Fludarabine (F) Long Term Follow up of US Intergroup Study E2997. BLOOD. vol. 116, 408-409.
Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR et al. (2010). Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997. BLOOD. vol. 116, 408-409.
Butler T, Gribben JG, Hodgson A (2010). Physician Scientists In Hematology: Hematologists' Experiences of Research and Recruitment to Academia - A Mixed Methods, Qualitative Approach. BLOOD. vol. 116, 1063-1064.
Jia L, Gopinathan G, Sukumar JT, Gribben JG (2010). Potentiation of Bortezomib Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I kappa B alpha Degradation. BLOOD. Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) (Orlando, FL) from: 04/12/2010 to: 07/12/2010, vol. 116, 57-57.
Jia L, Gopinathan G, Sukumar JT, Gribben JG (2010). Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-kappa B alpha Degradation. BLOOD. vol. 116, 57-57.
Jia L, Gopinathan G, Sukumar JT, Gribben JG (2010). Potentiation of Bortezomib-Induced Killing of Lymphoma Cells by Inhibition of Autophagy and Prevention of I-κBα Degradation. Blood. vol. 116, 116-116.
10.1182/blood.v116.21.116.116
Greaves P, Montoto S, Matthews J, Wilson A, Brown DLP, Lillington D, Gribben JG, Lister A (2010). Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose Therapy with Autologous Stem Cell Rescue for Lymphoma. BLOOD. vol. 116, 1420-1420.
Greaves P, Montoto S, Matthews J, Wilson A, Brown DLP, Lillington D, Gribben JG, Lister A(2010). Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose Therapy with Autologous Stem Cell Rescue for Lymphoma. Blood vol. 116, (21) 3459-3459.
10.1182/blood.v116.21.3459.3459
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Deanden CE et al. (2010). Rituximab Plus Chlorambucil In Patients with CD20-Positive B Cell Chronic Lymphocytic Leukemia (CLL) Final Response Analysis of An Open Label Phase H Study. BLOOD. Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) (Orlando, FL) from: 04/12/2010 to: 07/12/2010, vol. 116, 307-307.
Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE et al. (2010). Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study. BLOOD. vol. 116, 307-307.
Wrench D, Sangaralingam A, Tayyib H, Kang MK, Riain C, Gupta M, Carlotti E, Bodor C et al. (2010). TNERSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenviroment In Transformed Follicular Lymphoma. BLOOD. Conference: 52nd Annual Meeting of the American-Society-of-Hematology (ASH) (Orlando, FL) from: 04/12/2010 to: 07/12/2010, vol. 116, 349-349.
Wrench D, Sangaralingam A, Tayyib H, Kang MK, Riain C, Gupta M, Carlotti E, Bodor C et al. (2010). TNFRSF14 and EZH2 Mutations, Chr2p Gain and Copy Number Changes Targeting Genes Whose Proteins Interact with the Microenvironment In Transformed Follicular Lymphoma. BLOOD. vol. 116, 349-349.
Xing DX, Decker W, Li SF, Robinson S, Shah N, Yang H, Champlin RE, Parmar S et al. (2010). Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. BLOOD. vol. 116, 1018-1019.
Buchner M, Brantner P, Stickel N, Prinz G, Burger M, Bar C, Dierks C, Pfeifer D et al.(2010). The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia-CXCR4 antagonists as potential adjuvants for monoclonal antibodies. BRIT J HAEMATOL vol. 151, (2) 167-178.
10.1111/j.1365-2141.2010.08316.x
Gribben JG(2010). Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther vol. 10, (9) 1389-1394.
10.1586/era.10.127
Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN et al.(2010). Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother vol. 33, (7) 684-696.
10.1097/CJI.0b013e3181e475e9
Gribben JG(2010). Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. CURR OPIN ONCOL vol. 22, (5) 424-430.
10.1097/CCO.0b013e32833d5938
Czuczman M, Straus D, Gribben J, Bredenfeld H, Friedberg J, Bollard C (2010). Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. LEUKEMIA & LYMPHOMA. vol. 51, 41-49.
10.3109/10428194.2010.500083
Gribben J, Rosenwald A, Gascoyne R, Lenz G(2010). Targeting the microenvironment. Leuk Lymphoma vol. 51 Suppl 1, 34-40.
10.3109/10428194.2010.500072
Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F et al.(2010). Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood vol. 115, (24) 5053-5056.
10.1182/blood-2009-11-253260
O'Riain C, Smith P, Clear A, Wrench D, Gupta M, Bodor C, Matolcsy A, Calaminici M et al. (2010). EZH2 MUTATION IN FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 95, 167-167.
Wrench J, Skibola C, Matthews J, Cazier JB, Iqbal S, Carlotti E, Calaminici M, Davies A et al. (2010). SNP RS6457327 ON CHROMOSOME 6P PREDICTS TRANSFORMATION OF FOLLICULAR LYMPHOMA. HAEMATOLOGICA. vol. 95, 170-171.
Taussig D, Miraki-Moud F, Lister A, Bonnet D, Gribben J (2010). BONE MARROW FAILURE IN ACUTE MYELOID LEUKEMIA IS INDUCED BY A BLOCK IN DIFFERENTIATION OF NORMAL HEMATOPOIETIC STEM CELLS. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 13-13.
O' Riain C, Smith P, Clear A, Wrench D, Gupta M, Bodor C, Matolcsy A, Calaminici M et al. (2010). EZH2 MUTATION IN FOLLICULAR LYMPHOMA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 167-167.
Wrench J, Skibola C, Matthews J, Cazier JB, Iqbal S, Carlotti E, Calaminici M, Davies A et al. (2010). SNP RS6457327 ON CHROMOSOME 6P PREDICTS TRANSFORMATION OF FOLLICULAR LYMPHOMA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 95, 170-171.
Sziosarek PW, Delage B, O'Riain C, Hatzimichael E, Crook T, Calaminici M, Gribben JG, Lemoine N et al.(2010). Effect of inactivation of argininosuccinate synthetase on sensitivity of lymphomas to caspase-dependent apoptosis following treatment with arginine deiminase. JOURNAL OF CLINICAL ONCOLOGY vol. 28, (15)
Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE(2010). GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. BLOOD vol. 115, (19) 3939-3948.
10.1182/blood-2009-10-251660
Hillmen P, Gribben JG, Follows GA, Milligan DW, Sayala HA, Moreton P, Oscier D, Dearden CE et al. (2010). An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group. BRITISH JOURNAL OF HAEMATOLOGY. vol. 149, 2-2.
Butler T, Gribben JG(2010). Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. Blood Rev vol. 24, (3) 135-141.
10.1016/j.blre.2010.03.004
Auer RL, MacDougall F, Oakervee HE, Cavenagh JC, Gribben JG, Lister TA (2010). Fludarabine/cyclophosphamide non-myeloablative allogeneic stem cell transplantation for lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY. vol. 149, 70-70.
Jueliger S, Maharaj L, Iyengar S, Ghazaly E, Cutillas P, Auer R, Rommel C, Li L et al. (2010). Abstract 4489: The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies. 4489-4489.
10.1158/1538-7445.am10-4489
Liu F-T, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben JG, Agrawal SG(2010). CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood vol. 115, (15) 3079-3088.
10.1182/blood-2009-08-239483
https://qmro.qmul.ac.uk/xmlui/handle/123456789/1029
Ramsay AG, Gribben JG(2010). The 3 Rs in CLL immune dysfunction. Blood vol. 115, (13) 2563-2564.
10.1182/blood-2009-12-256909
Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H et al.(2010). Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood vol. 115, (10) 1976-1984.
10.1182/blood-2009-02-206565
Nagler A, Labopin M, Shimoni A, Mufti G, Cornelissen JJ, Blaise D, Janssen JJWM, Milpied N et al. (2010). Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT. BONE MARROW TRANSPLANTATION. vol. 45, S21-S22.
Hallam S, Gribben JG(2010). Stem cell transplantation in chronic lymphocytic leukaemia - steering a safe course over shifting sands. Best Pract Res Clin Haematol vol. 23, (1) 109-119.
10.1016/j.beha.2009.12.001
Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J et al.(2010). Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel. CL LYMPH MYELOM LEUK vol. 10, (1) 21-27.
10.3816/CLML.2010.n.002
Gribben JG(2010). How I treat CLL up front. Blood vol. 115, (2) 187-197.
10.1182/blood-2009-08-207126
Hillmen P, Gribben JG, Follows GA, Milligan DW, Sayala HA, Moreton P, Oscier D, Dearden CE et al. (2009). An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL). BLOOD. vol. 114, 1331-1332.
10.1182/blood.v114.22.3428.3428
Farren TW, Liu F-T, Stephens C, Tsitsikas D, Macey MG, Jenner M, Gribben JG, Agrawal SG(2009). CD160 Expression in B-Cell Lymphoproliferative Disorders: Derivation and Validation of a New Three-Antigen Scoring System Improving Diagnostic Precision in B-Cell Malignancies. Blood vol. 114, (22) 4382-4382.
10.1182/blood.v114.22.4382.4382
Mohty M, Labopin M, Janssen JJWM, Mufti GJ, Cornelissen JJ, Milpied NJ, Sengeloev H, Blaise D et al. (2009). Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT. BLOOD. vol. 114, 489-489.
Xing DX, Ramsay AG, Decker W, Li SF, Robinson S, Yang H, Shah N, Hosing C et al. (2009). Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2R gamma(null) (NSG) Mice as a Model. BLOOD. vol. 114, 936-936.
Xing DX, Ramsay AG, Decker W, Li SF, Robinson S, Yang H, Bollard CM, Gribben JG et al. (2009). Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia. BLOOD. vol. 114, 1180-1181.
Butler T, Wiseman C, Farren T, Gribben JG, Agrawal SG(2009). Expression of Surface IgG Is High in Chronic Lymphocytic Leukaemia, and Co-Expression with IgM Confers a Worse Prognosis. Blood vol. 114, (22) 4371-4371.
10.1182/blood.v114.22.4371.4371
Xing DX, Ramsay AG, Decker W, Li SF, Robinson S, Yang H, Gribben JG, Shpall EJ (2009). Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia. BLOOD. vol. 114, 1044-1044.
Liu F-T, Jia L, Farren T, Giustiniani J, Bensussan A, Gribben JG, Agrawal SG(2009). Spontaneous in Vitro Death of CLL Cells Can Be Prevented by Mitochondrial Stabilization Via CD160 Signaling. Blood vol. 114, (22) 4372-4372.
10.1182/blood.v114.22.4372.4372
Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, Rai KR, Larson RA et al. (2009). Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. BLOOD. vol. 114, 226-226.
Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, Rai KR, Larson RA et al.(2009). Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. Blood vol. 114, (22) 539-539.
10.1182/blood.v114.22.539.539
Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM et al.(2009). Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood vol. 114, (21) 4713-4720.
10.1182/blood-2009-04-217687
Riches JC, Gribben JG(2009). Interesting times in the diagnosis and treatment of CLL. Oncology (Williston Park) vol. 23, (12) 1043-1046.
O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, Koziner B, Chanan-Khan AA, Seymour JF et al.(2009). 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol vol. 27, (31) 5208-5212.
10.1200/JCO.2009.22.5748
Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA et al.(2009). Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood vol. 114, (18) 3909-3916.
10.1182/blood-2009-02-206946
Gribben JG(2009). One step back but 2 steps forward. Blood vol. 114, (16) 3359-3360.
10.1182/blood-2009-08-234146
Carlotti E, Gribben JG(2009). Stem cell mimicry: key to transformation?. Blood vol. 114, (15) 3133-3134.
10.1182/blood-2009-08-236786
O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L et al.(2009). Array-based DNA methylation profiling in follicular lymphoma. Leukemia vol. 23, (10) 1858-1866.
10.1038/leu.2009.114
Ramsay AG, Gribben JG(2009). Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. HAEMATOL-HEMATOL J vol. 94, (9) 1198-1202.
10.3324/haematol.2009.009274
Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM(2009). Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol vol. 146, (5) 574-576.
10.1111/j.1365-2141.2009.07763.x
Le Dieu R, Taussig D, Lister TA, Gribben JG(2009). Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. J Immunol Methods vol. 348, (1-2) 95-100.
10.1016/j.jim.2009.06.010
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, Chevalier N, Vallat L et al.(2009). Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. CANCER RES vol. 69, (13) 5424-5432.
10.1158/0008-5472.CAN-08-4252
Wendtner CM, Mahadevan D, Coutre S, Hillmen P, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F et al. (2009). A PHASE I DOSE-ESCALATION OF LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 94, 371-372.
Cotter F, Smith DA, Boyd TE, Richards DA, Alemany C, Loesch D, Salogub G, Tidmarsh GF et al. (2009). Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia. JOURNAL OF CLINICAL ONCOLOGY. vol. 27,
Cotter F, Smith DA, Boyd TE, Richards DA, Alemany C, Loesch D, Salogub G, Tidmarsh GF et al.(2009). Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia. J Clin Oncol vol. 27, (15_suppl)
10.1200/jco.2009.27.15_suppl.7006
Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM et al.(2009). E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A vol. 106, (15) 6250-6255.
10.1073/pnas.0901166106
Gorgun G, Ramsay AG, Holderried TAW, Zahrieh D, Dieu RL, Liu F, Quackenbush J, Croce CM et al.(2009). Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America vol. 106, (15) 6250-6255.
10.1073/pnas.0901166106
Carlotti E, Wrench D, Matthews J, Iqbal S, Davies A, Norton A, Hart J, Lai R et al.(2009). Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone. Blood vol. 113, (15) 3553-3557.
10.1182/blood-2008-08-174839
O'Shea D, O'Riain C, Gupta M, Waters R, Yang Y, Wrench D, Gribben J, Rosenwald A et al.(2009). Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood vol. 113, (10) 2298-2301.
10.1182/blood-2008-08-174953
Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ(2009). Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res vol. 33, (3) 368-376.
10.1016/j.leukres.2008.05.022
Gribben JG, Hallek M(2009). Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol vol. 144, (6) 818-831.
10.1111/j.1365-2141.2008.07557.x
Tsitsikas DA, Oakervee H, Cavenagh J, Agrawal S, Gribben J, Mattes F (2009). Treatment of respiratory syncytial virus infection with nebulised ribavirin and the humanised monoclonal antibody palivizumab in eight haemopoietic stem cell transplant recipients. BONE MARROW TRANSPLANTATION. vol. 43, S252-S253.
Xing D, Ramsary AG, Gribben JG, Decker WK, Li S, Robinson SN, Yang H, David S et al. (2009). DEFECTIVE IMMUNE SYNAPSE FORMATION OF UMBILICAL CORD BLOOD-DERIVED NATURAL KILLER CELL S IS ABROGATED BY EX VIVO EXPANSION. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. vol. 15, 117-118.
10.1016/j.bbmt.2008.12.362
Decker WK, Li S, Xing D, Robinson SN, Yang H, Steiner D, Lapusbin R, Ramsay AG et al. (2009). GENERATION OF CLL-SPECIFIC CTL EFFECTORS FROM PARTIALLY HLA-MATCHED UMBILICAL CORD BLOOD GRAFTS USING CD154-TRANSDUCED CLL CELL S AS APCS. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. vol. 15, 123-123.
10.1016/j.bbmt.2008.12.378
Elter T, Vehreschild J, Gribben J, Cornely O, Engert A, Hallek M(2009). Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. ANN HEMATOL vol. 88, (2) 121-132.
10.1007/s00277-008-0566-9
Wrench D, Waters R, Carlotti E, Iqbal S, Matthews J, Calaminici M, Gribben J, Lister TA et al.(2009). Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma. HAEMATOL-HEMATOL J vol. 94, (1) 148-150.
10.3324/haematol.13533
Gribben JG (2009). Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant. vol. 15, 53-58.
10.1016/j.bbmt.2008.10.022
Hallam S, Gribben JG(2009). Transplantation in chronic lymphocytic leukemia: timing and expectations. Clin Lymphoma Myeloma vol. 9 Suppl 3, S186-S193.
10.3816/CLM.2009.s.010
Brown JR, Rassenti L, Neuberg D, Greaves A, Byrd JC, Grever MR, Gribben JG, Kay NE et al. (2008). Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. BLOOD. vol. 112, 1071-1072.
Ramsay AG, Clear AJ, Fatah R, Gribben JG (2008). Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells. BLOOD. vol. 112, 327-327.
Brown JR, Stevenson K, Kim HT, Armand P, Cutler C, Fisher DC, Ho V, Koreth J et al. (2008). Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. BLOOD. vol. 112, 357-358.
Ramsay AG, Xing DX, Decker WK, Burks JK, Wierda WG, Gribben JG, Shpall EJ (2008). Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells. BLOOD. vol. 112, 813-813.
10.1182/blood.V112.11.885.885
Ramsay AG, Svensson L, Hogg N, Gribben JG (2008). Defective T Cell Migration in Chronic Lymphocytic Leukemia Is Repaired by Lenalidomide. BLOOD. vol. 112, 1069-1069.
Le Dieu R, Ramsay AG, Taussig D, Mitter R, Gribben JG (2008). Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis. BLOOD. vol. 112, 433-433.
Le Dieu R, Ramsay AG, Taussig D, Mitter R, Gribben JG (2008). Differential Gene Expression Profile Identifies the Nature of T Cell Defects in AML Patients at Diagnosis. Blood. vol. 112, 1186-1186.
10.1182/blood.v112.11.1186.1186
Agrawal SG, Liu FT, Giustiniani J, Jia L, Gribben JG, Bensussan A (2008). Dual Action of CD160 on CLL Cells: Giving Life to Prepare for Death!. BLOOD. vol. 112, 726-726.
Agrawal SRG, Liu F-T, Giustiniani J, Jia L, Gribben JG, Bensussan A(2008). Dual Action of CD160 on CLL Cells: Giving Life to Prepare for Death!. Blood vol. 112, (11) 2088-2088.
10.1182/blood.v112.11.2088.2088
Xing DX, Ramsay AG, Gribben JG, Decker WK, Burt JK, Li SF, Simon SN, Yang H et al. (2008). Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. BLOOD. vol. 112, 999-999.
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Goff LK, Lister TA, Gribben JG(2008). Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma. Blood vol. 112, (11) 2822-2822.
10.1182/blood.v112.11.2822.2822
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Goff LK, Lister TA, Gribben JG (2008). Extended Focal Imaging Reveals An Improved Gauge of Angiogenic Activity and Highlights the Role of Angiogenesis in Survival and Time to Transformation in Follicular Lymphoma. BLOOD. vol. 112, 975-975.
Ramsay AG, Clear AJ, Fatah R, Gribben JG (2008). Lenalidomide Repairs Suppressed T Cell Immunological Synapse Formation in Follicular Lymphoma. Conference: 50th Annual Meeting of the American- Society-of-Hematology (San Francisco, CA) from: 06/12/2008 to: 09/12/2008,
10.1182/blood.v112.11.885.885
Wendtner CM, Mahadevan D, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Uharek L, Furman RR et al.(2008). Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood vol. 112, (11) 2104-2104.
10.1182/blood.v112.11.2104.2104
Wendtner CM, Mahadevan D, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Uharek L, Furman RR et al. (2008). Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic-Lymphocytic-Leukemia. BLOOD. vol. 112, 732-732.
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholomee K, Chevalier N, Vallat L, Timmer J et al. (2008). Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. BLOOD. vol. 112, 203-203.
Liu F-T, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben JG, Newland AC, Jia L(2008). Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood vol. 112, (9) 3835-3846.
10.1182/blood-2008-04-150227
https://qmro.qmul.ac.uk/xmlui/handle/123456789/1075
Gribben JG(2008). Role of allogeneic hematopoietic stem-cell transplantation in chronic lymphocytic leukemia. J Clin Oncol vol. 26, (30) 4864-4865.
10.1200/JCO.2008.17.7733
O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A et al.(2008). The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood vol. 112, (8) 3126-3129.
10.1182/blood-2008-05-154013
Wrench D, Gribben JG(2008). Stem cell transplantation for non-Hodgkin's lymphoma. Hematol Oncol Clin North Am vol. 22, (5) 1051-xi.
10.1016/j.hoc.2008.07.007
Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC(2008). Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood vol. 112, (6) 2232-2241.
10.1182/blood-2008-03-143636
Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR et al.(2008). Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. BLOOD vol. 112, (5) 1923-1930.
10.1182/blood-2007-05-092882
Ramsay AG, Gribben JG(2008). Vaccine therapy and chronic lymphocytic leukaemia. Best Pract Res Clin Haematol vol. 21, (3) 421-436.
10.1016/j.beha.2008.07.005
Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H et al.(2008). Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood vol. 112, (3) 568-575.
10.1182/blood-2007-10-118331
Proto-Siqueira R, Panepucci RA, Careta FP, Lee A, Clear A, Morris K, Owen C, Rizzatti EG et al.(2008). SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. BLOOD vol. 112, (2) 394-397.
10.1182/blood-2007-11-124065
Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG(2008). Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest vol. 118, (7) 2427-2437.
10.1172/JCI35017
de Jong D, Lee AM, Hauptmann M, Heisterkamp S, Calaminici M, Gribben JG, Kerst M, Lister TA (2008). Changes in follicular lymphoma are related to time to transformation to diffuse large B-cell lymphoma. ANNALS OF ONCOLOGY. vol. 19, 111-111.
Cotter FE, Gribben J, Streetly M, Auer R, Smith D, Alemany C, Loesch D, Boyd TE et al. (2008). Clinical caspase activation in CLL by GCS-100, a novel carbohydrate, in a phase 2 study. ANNALS OF ONCOLOGY. vol. 19, 90-90.
Lee AM, Clear AJ, Morris KJ, Calaminici MR, Matthews J, Gribben JG, Lister TA (2008). Examination of changes in tumour microenvironment of follicular lymphoma using serial sample tissue microarrays. ANNALS OF ONCOLOGY. vol. 19, 179-179.
Wrench D, Waters R, Matthews J, Calaminici M, Carlotti E, Iqbal S, Gribben J, Lister A et al. (2008). MDM2 309 and TP53 ARG72PRO SNP genotypes do not predict clinical outcome of follicular lymphoma. ANNALS OF ONCOLOGY. vol. 19, 178-178.
O'Riain C, O'Shea D, Yang Y, Gribben J, Afari J, Mein CA, Crook T, Smith P et al. (2008). Methylation profiling in 158 cases of previously untreated follicular lymphoma (FL). ANNALS OF ONCOLOGY. vol. 19, 101-101.
Gribben JG(2008). New agents in chronic lymphocytic leukemia. Clin Adv Hematol Oncol vol. 6, (6) 409-468.
O'Shea D, O'Riain C, MacDougall F, Gribben J, Young BD, Rosenwald A, Rimsza L, Roberts R et al. (2008). SNP array genotyping in 182 diagnostic follicular lymphoma cases identifies sites of AUPD associated with overall survival and risk of transformation. ANNALS OF ONCOLOGY. vol. 19, 111-111.
Lee AM, Clear AJ, Morris KJ, Calaminici MR, Matthews J, Gribben JG, Lister TA (2008). The impact of tumour microenvironment in diagnostic follicular lymphoma samples using tissue microarrays. ANNALS OF ONCOLOGY. vol. 19, 126-126.
Gribben J (2008). Transforming the outlook for CLL patients. ANNALS OF ONCOLOGY. vol. 19, 262-262.
Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR et al.(2008). Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. BLOOD vol. 111, (10) 5101-5108.
10.1182/blood-2007-12-130229
Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kazmi M et al.(2008). The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology vol. 13, (2) 119-127.
10.1179/102453308X315915
Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG et al.(2008). Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. BLOOD vol. 111, (6) 3137-3144.
10.1182/blood-2007-02-073130
Liu F-T, Agrawal SG, Gribben JG, Ye H, Du M-Q, Newland AC, Jia L(2008). Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood vol. 111, (5) 2797-2805.
10.1182/blood-2007-08-110445
https://qmro.qmul.ac.uk/xmlui/handle/123456789/1076
Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, Du MQ, Syndercombe-Court D et al.(2008). Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. BLOOD vol. 111, (5) 2790-2796.
10.1182/blood-2007-10-110460
https://qmro.qmul.ac.uk/xmlui/handle/123456789/1077
Davies J, Gribben J, Brennan L, Nadler L, Guinan E (2008). ALLOANERGIZED HLA-MISMATCHED BONE MARROW TRANSPLANTATION - LOW INCIDENCE OF CLINICALLY SIGNIFICANT GVHD AND VIRAL INFECTION RESULTING IN LONG TERM DISEASE FREE SURVIVAL. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Conference: Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation (San Diego, CA) from: 13/02/2008 to: 17/02/2008, vol. 14, 16-17.
10.1016/j.bbmt.2007.12.046
Ramsay AG, Gorgun G, Holderried TAW, Zahrieh D, Liu FL, Quackenbush J, Croce CM, Gribben JG (2008). A Mouse Model for Immunotherapeutic Reversal of Leukemia-induced T Cell Dysfunction. Conference: 50th ASH Annual Meeting and Exposition (Moscone Center, San Francisco, CA) from: 06/12/2008 to: 09/12/2008,
Butler T, Gribben JG(2008). Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients. Expert Opinion on Medical Diagnostics vol. 2, (1) 101-112.
10.1517/17530059.2.1.101
Le Dieu R, Gribben JG(2008). Chronic Lymphocytic Leukaemia. Hematopoietic Stem Cell Transplantation, Editors: Soiffer, RJ, Edition. 1, Springer
Gribben JG(2008). Chronic lymphocytic leukemia: an historical perspective. Hematology Am Soc Hematol Educ Program
10.1182/asheducation-2008.1.443
Gribben JG(2008). Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program444-449.
10.1182/asheducation-2008.1.444
Buske C, Gisselbrecht C, Gribben J, Letai T, McLaughlin P, Wilson W (2008). Refining the treatment of follicular lymphoma. LEUKEMIA & LYMPHOMA. vol. 49, 18-26.
10.1080/10428190802311409
Stevens JM, Syndercombe-Court D, Oakervee HE, McCloskey D, Jenner MJ, Gribben JG, Cavenagh JD(2007). Development of original donor cell leukemia after successful engraftment from a second donor. BLOOD vol. 110, (13) 4621-4622.
10.1182/blood-2007-07-104240
Auer RL, Gribben J, Cotter FE(2007). Emerging therapy for chronic lymphocytic leukaemia. Br J Haematol vol. 139, (5) 635-644.
10.1111/j.1365-2141.2007.06877.x
Doffman SR, Griffiths LJ, Lim C, Vinnicombe S, Wilks M, Gribben JG, Griffiths MJ, Agrawal SG(2007). A Novel Non-Invasive Method of Detecting Galactomannan in Suspected Pulmonary Aspergillosis. Blood vol. 110, (11) 3862-3862.
10.1182/blood.v110.11.3862.3862
Doffman SR, Griffiths LJ, Lim C, Vinnicombe S, Wilks M, Gribben JG, Griffiths MJ, Agrawal SG (2007). A novel non-invasive method of detecting galactomannan in suspected pulmonary aspergillosis. BLOOD. vol. 110, 33B-33B.
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Proto-Siqueira R, Goff LK, Lister TA et al.(2007). Angiogenesis Assessed in Tissue Microarrays of Diagnostic Follicular Lymphoma Correlates with Outcome. Blood vol. 110, (11) 2609-2609.
10.1182/blood.v110.11.2609.2609
Clear AJ, Lee AM, Morris KJ, Calaminici M, Macdougall F, Proto-Siqueira R, Goff LK, Lister TA et al. (2007). Angiogenesis assessed in tissue microarrays of diagnostic follicular lymphoma correlates with outcome. BLOOD. vol. 110, 768A-768A.
Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, Du MQ, Court DS et al. (2007). Bax degradation activity is a novel poor prognosis marker of chronic lymphocytic leukemia. BLOOD. vol. 110, 908A-908A.
10.1182/blood.v110.11.3087.3087
Le Dieu R, Taussig D, MacDougal F, Lister A, Gribben JG(2007). CD3+/CD56+ Cells, but Not Natural Killer T Cells, Are Increased in Peripheral Blood of Untreated Patients with Leukemia. Blood vol. 110, (11) 1815-1815.
10.1182/blood.v110.11.1815.1815
Le Dieu R, Taussig D, MacDougal F, Lister A, Gribben JG (2007). CD3+/CD56+cells, but not natural killer T cells, are increased in peripheral blood of untreated patients with leukemia. BLOOD. vol. 110, 538A-538A.
Giustiniani J, Wiseman C, Farren T, Gribben JG, Agrawal SG (2007). CLL cell proliferation and IL-6 production are regulated by CD160-MHC class I interactions offering new therapeutic targets. BLOOD. vol. 110, 342A-342A.
10.1182/blood.v110.11.1126.1126
Carlotti E, Wrench D, Iqbal S, O¿Shea D, Davies A, Virappane P, Hart J, Lai R et al.(2007). Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma. Blood vol. 110, (11) 181-181.
10.1182/blood.v110.11.181.181
Carlotti E, Wrench D, Iqbal S, O'Shea D, Davies A, Virappane P, Hart J, Lai R et al. (2007). Determining the mechanism of transformation of follicular lymphoma into diffuse large B cell lymphoma. BLOOD. vol. 110, 61A-61A.
Wiseman C, Giustiniani J, Mikkelsen L, Macey M, Goff L, Gribben J, Agrawal S (2007). High frequency of surface immunoglobulin IgG in B-Cell chronic lymphocytic leukaemia. BLOOD. vol. 110, 245B-245B.
10.1182/blood.v110.11.4685.4685
Ramsay AG, Lee AM, Gribben JG (2007). Impaired actin polymerization results in defective immunological synapse formation in T cells in chronic lymphocytic leukemia. BLOOD. vol. 110, 106A-107A.
10.1182/blood.v110.11.338.338
Proto-Siqueira R, Panepucci RA, Careta FP, Rizzatti EG, Lee A, Clear A, Morris K, Falcao RP et al. (2007). SAGE analysis demonstrates increased expression of TOSO contributing to Fas mediated resistance in CLL. BLOOD. vol. 110, 340A-340A.
10.1182/blood.v110.11.1121.1121
Ghia LEM, Rassenti LZ, Widhopf GF, Silverman GJ, Neuberg DS, Keating MJ, Wierda WG, Gribben JG et al. (2007). Stereotypie IGHV3-21/IGLV3-21 antibodies expressed in high-risk chronic lymphocytic leukemia bind peptostreptococcus magnus protein. BLOOD. vol. 110, 227A-228A.
Vallat L, Pionneau C, Jacob F, Davi F, Leblond V, Gribben JG, Merle-Beral H (2007). Temporal proteomic analysis of CLL B cell response to antigen receptor stimulation. BLOOD. vol. 110, 344A-344A.
Gribben JG (2007). Do we need allogeneic transplantation in HL?. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. vol. 92, 19-19.
Gribben JG(2007). Management of Haematological Malignancies. The Cancer Handbook,
Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS(2007). Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant vol. 13, (9) 1057-1065.
10.1016/j.bbmt.2007.05.012
Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD et al.(2007). Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood vol. 110, (5) 1607-1611.
10.1182/blood-2006-09-045369
Gribben JG(2007). Stem-cell transplantation in chronic lympocytic leukaernia. BEST PRACT RES CL HA vol. 20, (3) 513-527.
10.1016/j.beha.2007.03.003
Rohatiner AZS, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM et al. (2007). Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. vol. 25, 2554-2559.
10.1200/JCO.2006.09.8327
Gribben JG(2007). How I treat indolent lymphoma. BLOOD vol. 109, (11) 4617-4626.
10.1182/blood-2006-10-041863
Vallat LD, Park Y, Li C, Gribben JG(2007). Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood vol. 109, (9) 3989-3997.
10.1182/blood-2006-09-045377
Wallis LC, Streetly MJ, Auer R, Gribben J, Zhang D, Hankins WD, Zadeh SM, Cotter FE (2007). Dynamic assessment of apoptosis for in vitro design of bortezomib combination therapies for lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY. vol. 137, 63-63.
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS et al.(2007). Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol vol. 25, (7) 799-804.
10.1200/JCO.2006.08.3089
Le Dieu R, Gribben JG(2007). Transplantation in chronic lymphocytic leukemia. Curr Hematol Malig Rep vol. 2, (1) 56-63.
10.1007/s11899-007-0008-0
Zirlik KM, Zahrieh D, Neuberg D, Gribben JG(2006). Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood vol. 108, (12) 3865-3870.
10.1182/blood-2006-04-014415
Lee AM, Clear A, Calaminici M, Macdougall F, Goff L, Gribben JG (2006). Increased CD69 and decreased CD4 expressing cells in tissue microarray (TMA) in diagnostic lymph node biopsies are associated with poor outcome in CLL/SLL. BLOOD. vol. 108, 787A-787A.
10.1182/blood.v108.11.2781.2781
Brown JR, Gribben JG, Feng Y, Neuberg D, Mauch P, Nadler LM, Freedman AS (2006). Long-term follow-up of autologous bone marrow transplantation for follicular lymphoma in first remission: Bone marrow involvement at harvest and PCR detectable disease after ex vivo purging predict relapse. BLOOD. vol. 108, 865A-865A.
10.1182/blood.v108.11.3041.3041
Rassenti LZ, Neuberg DS, Huynh L, Wierda WG, Gribben JG, Brown JR, Flinn IW, Rai KR et al. (2006). Relative value of CD38 and ZAP-70 versus immunoglobutin mutation status in predicting early disease progression in chronic lymphocytic leukemia. BLOOD. vol. 108, 786A-787A.
10.1182/blood.v108.11.2778.2778
Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning ML, Rassenti L, Greaves A et al. (2006). Self-administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLL. BLOOD. vol. 108, 804A-804A.
10.1182/blood.v108.11.2839.2839
Zirlik K, Burger M, Brantner P, Prinz G, Buchner M, Gribben JG, Veelken H (2006). Stromal cells protect B-CLL cells from killing by antigen-specific cytotoxic T cells. BLOOD. vol. 108, 796A-797A.
10.1182/blood.v108.11.2814.2814
Ghia EM, Rassenti LZ, Widhopf GF, Neuberg DS, Keating MJ, Wierda WG, Gribben JG, Brown JR et al. (2006). Study of VH3-21 in a large cohort of chronic lymphocytic leukemia patients reveals evidence for antigen selection and confirms its predictive value for early disease progression. BLOOD. vol. 108, 785A-785A.
10.1182/blood.v108.11.2774.2774
Gilleece MH, Pearce R, Linen DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kamzi M et al. (2006). Utilisation of stem cell transplantation for lymphoplasmacytic lymphoma in the UK. BLOOD. vol. 108, 844A-845A.
10.1182/blood.v108.11.2980.2980
Wallis LC, Streetly MJ, Auer R, Gribben J, Zhang D, Hankins WD, Zadeh SM, Cotter FE (2006). Dynamic Assessment of Apoptosis for In Vitro Design of Bortezomib Combination Therapies for Lymphoid Malignancies. Blood. vol. 108, 2494-2494.
10.1182/blood.v108.11.2494.2494
Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ et al. (2006). Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. vol. 24, 5052-5059.
10.1200/JCO.2006.06.4642
Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ et al.(2006). Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant vol. 12, (10) 1056-1064.
10.1016/j.bbmt.2006.06.004
Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng SH, Esseltine DL et al.(2006). Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. CANCER vol. 107, (5) 916-924.
10.1002/cncr.22097
Gribben JG(2006). Of mice and men... BLOOD vol. 108, (4) 1115-1116.
10.1182/blood-2006-06-025957
Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR(2006). Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis vol. 43, (1) 16-24.
10.1086/504811
Grever MR, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Appelbaum FR, Larson RA et al. (2006). Select high risk genetic features predict earlier progression following chemotherapy in chronic lymphocytic leukemia: Prospective randomized trial (Intergroup E2997) to evaluate justification for risk-adapted therapy. JOURNAL OF CLINICAL ONCOLOGY. vol. 24, 342S-342S.
Davies JK, Taussig DC, Oakervee H, Davies AJ, Agrawal SG, Gribben JG, Lister TA, Cavenagh JD(2006). Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. J Clin Oncol vol. 24, (14) e23-e25.
10.1200/JCO.2006.05.7281
Ho VT, Kim HT, Liney D, Milford E, Gribben J, Cutler C, Lee SJ, Antin JH et al. (2006). HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. BONE MARROW TRANSPLANTATION. vol. 37, 845-850.
10.1038/sj.bmt.1705315
Le Dieu R, Gribben J(2006). Vaccine- and immune-based therapy in chronic lymphocytic leukemia. Semin Oncol vol. 33, (2) 220-229.
10.1053/j.seminoncol.2005.12.012
Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA et al.(2006). Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol vol. 24, (3) 437-443.
10.1200/JCO.2005.03.1021
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P et al.(2005). Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood vol. 106, (13) 4389-4396.
10.1182/blood-2005-05-1778
Faderl S, Coutré S, Byrd JC, Dearden C, Denes A, Dyer MJS, Gregory SA, Gribben JG et al.(2005). The evolving role of alemtuzumab in management of patients with CLL. Leukemia vol. 19, (12) 2147-2152.
10.1038/sj.leu.2403984
Gorgun G, Holderried TAW, Ledieu R, Zahrieh D, Gribben JG(2005). CLL Cells in TCL1 Transgenic Mice Induce Similar Defects in CD4 and CD8 T Cells to Those Observed in Patients with CLL. Blood vol. 106, (11) 50-50.
10.1182/blood.v106.11.50.50
Gorgun G, Holderried TAW, Ledieu R, Zahrieh D, Gribben JG (2005). CLL cells in TCL1 transgenic mice induce similar defects in CD4 and CD8 T cells to those observed in patients with CLL. BLOOD. vol. 106, 19A-19A.
Goff LK, Lee AM, Clear A, Calaminici M, Davies AJ, Jordan S, Macdougall F, Matthews J et al.(2005). Discrimination of Long and Short Survival in Follicular Lymphoma (FL) Patients by Incidence of FOXP3 and Perifollicular Incidence of CD4 and CD7 Using Immunohistochemistry on Tissue Microarray (TMA) of Diagnostic Lymph Nodes (LN). Blood vol. 106, (11) 603-603.
10.1182/blood.v106.11.603.603
Fukuda T, Neuberg DS, Huynh L, Rassenti LZ, Toy TL, Rai KR, Keating MJ, Gribben JG et al. (2005). Expression of T cell co-stimulator (ICOS) and its ligand and disease progression in B-cell chronic lymphocytic leukemia. BLOOD. vol. 106, 826A-826A.
Gribben J, Stephans K, Marshal B (2005). Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study. BLOOD. vol. 106, 343B-343B.
Brown JR, Li S, Kim H, Fisher DC, Cutler C, Ho V, Lee SJ, Ritz J et al.(2005). High Levels of Early Donor Chimerism and Treatment-Responsive Disease Predict Improved Progression-Free Survival Following Non-Myeloablative Transplantation for Advanced CLL. Blood vol. 106, (11) 560-560.
10.1182/blood.v106.11.560.560
Brown JR, Li SL, Kim H, Fisher DC, Cutler C, Ho V, Lee SJ, Ritz J et al. (2005). High levels of early donor chimerism and treatment-responsive disease predict improved progression-free survival following non-myeloablative transplantation for advanced CLL. BLOOD. vol. 106, 166A-167A.
Ledieu R, Gorgun G, Gribben JG (2005). In vivo demonstration of donor idiotype specific T cells that kill primary CLL cells post allogeneic transplant. BLOOD. vol. 106, 23A-23A.
Guinan EC, Gribben JG, Brennan LL, Nadler LM(2005). Patients (Pts) Surviving Haploidentical Stem Cell Transplantation (SCT) after Ex Vivo Costimulatory Blockade To Induce Anergy Experience Few Long-Term Complications. Blood vol. 106, (11) 599-599.
10.1182/blood.v106.11.599.599
Guinan EC, Gribben JG, Brennan LL, Nadler LM (2005). Patients (Pts) surviving haploidentical stem cell transplantation (SCT) after ex vivo costimulatory blockade to induce anergy experience few long-term complications. BLOOD. vol. 106, 178A-178A.
Mauerer K, Gorgun G, Zahrieh D, Gribben JG (2005). Successful generation of cytotoxic T-cells that kill CLL cells using heteroclitic peptides is independent of the native peptide binding affinity to HLA-A*0201. BLOOD. vol. 106, 20A-21A.
Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K et al.(2005). Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. LEUKEMIA RES vol. 29, (11) 1253-1257.
10.1016/j.leukres.2005.03.010
Li A, Goldwasser MA, Zhou J, Armstrong SA, Wang H, Dalton V, Fletcher JA, Sallan SE et al.(2005). Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol vol. 131, (2) 185-192.
10.1111/j.1365-2141.2005.05754.x
Le Dieu R, Gribben J(2005). CD40 activation: lessons for HIV immunotherapy from malignancies?. J HIV Ther vol. 10, (3) 51-55.
Görgün G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG(2005). Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest vol. 115, (7) 1797-1805.
10.1172/JCI24176
Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U et al.(2005). Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res vol. 11, (12) 4430-4436.
10.1158/1078-0432.CCR-04-2111
Gribben JG, Stephenson JJ, Bartlett NL, Milder MS, Boccia RV, Redfern C, Mizuno VM, Hillson J et al. (2005). A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). JOURNAL OF CLINICAL ONCOLOGY. vol. 23, 168S-168S.
Gribben JG (2005). Combination therapy with MabCampath (R): Moving forward. ANNALS OF ONCOLOGY. vol. 16, 255-255.
Mauerer K, Zahrieh D, Gorgun G, Li A, Zhou J, Ansén S, Rassenti LZ, Gribben JG(2005). Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br J Haematol vol. 129, (4) 499-510.
10.1111/j.1365-2141.2005.05480.x
Zhou J, Mauerer K, Farina L, Gribben JG(2005). The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci vol. 10, 1581-1596.
10.2741/1642
Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D et al.(2005). Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. BLOOD vol. 105, (5) 2235-2238.
10.1182/blood-2003-12-4399
Davies AJ, Gribben JG(2005). Hematopoietic stem cell transplantation in non-Hodgkin lymphoma. CURR OPIN ORGAN TRAN vol. 10, (1) 35-39.
10.1097/01.mot.0000152690.24829.ca
Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S et al.(2005). Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. BLOOD vol. 105, (4) 1810-1814.
10.1182/blood-2004-05-1947
Gribben JG, Bartlett NL, Stephenson JJ, Milder MS, Boccia RV, Redfern C, Mizuno VM, Berenson RJ et al. (2005). A phase II study of Xcellerated T cells (TM) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. vol. 11, 76-76.
10.1016/j.bbmt.2004.12.225
Darby A, Gribben JG(2005). Follicular Lymphoma. Lymphoma, vol. 115,
Darby A, Gribben JG(2005). Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation. Methods Mol Med vol. 115, 315-331.
10.1385/1-59259-936-2:315
Gribben JG(2005). Salvage therapy for CLL and the role of stem cell transplantation. Hematology Am Soc Hematol Educ Program292-298.
10.1182/asheducation-2005.1.292
Zhou J, Mauerer K, Farina L, Gribben JG(2005). The role of the tumor microenvironment in hematological malignancies and implication for therapy. Frontiers in Bioscience vol. 10, (2) 1581-1596.
10.2741/1642
Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D, Gribben JG(2004). Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood vol. 104, (13) 4002-4009.
10.1182/blood-2004-02-0494
Freedman AS, Gribben JG, Neuberg D, Li S, Kim H, Mauch P, Nadler LM (2004). Autologous bone marrow transplantation for follicular lymphoma in first remission: Long term follow up of two sequential trials with standard dose and high dose CHOP induction. BLOOD. vol. 104, 396B-396B.
Rassenti LZ, Neuberg DS, Keating MJ, Gribben JG, Flinn IW, Rai KR, Byrd JC, Kay NE et al. (2004). CD38 compared with ZAP-70 or immmunoglobulin mutation status as predictor of disease progression in chronic lymphocytic leukemia. BLOOD. vol. 104, 767A-768A.
Holderried TAW, Gorgun G, Gribben JG (2004). Cell contact with CLL cells induces defects in T cell differentiation and effector pathways: Impact of silencing specific cytokine production. BLOOD. vol. 104, 273A-274A.
10.1182/blood.v104.11.955.955
Kitada S, Reed JC, David MLI, Neuberg DS, Gribben JG, Dewald GW, Flinn IW, Appelbaum FR et al. (2004). Critical molecular studies to strategically plan therapy in chronic lymphocytic leukemia (CLL): Correlating cellular proteins with defined prognostic patient subsets and their response to treatment. BLOOD. vol. 104, 274A-274A.
10.1182/blood.v104.11.956.956
Mauerer K, Zahrieh D, Gorgun G, Li AH, Zhou JB, Rassenti L, Gribben JG (2004). Distinct VDJ-H gene usage between mutated and unmutated patients in B-CLL: Implications for pathogenesis and correlation with clinical outcome. BLOOD. vol. 104, 278A-278A.
10.1182/blood.v104.11.970.970
Rizouli V, Zahrieh D, Gorgun G, Holderried TAW, Croce C, Gribben JG (2004). Gene expression profiling identifies similar CD4(+) and CD8(+) T cell defects in TCL1 transgenic mice after development of CLL to those observed in patients with CLL. BLOOD. vol. 104, 55A-55A.
10.1182/blood.v104.11.180.180
Zhou JB, Xia ZN, Li AH, Gribben JG (2004). Mapping low molecular weight plasma proteome of chronic lymphoblastic leukemia patients using MALDI-TOF mass spectrometry. BLOOD. vol. 104, 528A-528A.
10.1182/blood.v104.11.1910.1910
Li AH, Zhou JB, Wang HJ, Goldwasser MA, Lyons C, Sallan SE, Silverman LB, Gribben JG (2004). Molecular analysis of T-cell receptor gene rearrangements in children with T-cell acute lymphoblast leukemia on DFCI ALL consortium protocol 95-01. BLOOD. vol. 104, 308A-308A.
Grever MR, Lucas DM, Dewald GW, Neuberg DS, Flinn IW, Appelbaum FR, Larson RA, Tallman MS et al. (2004). Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features: Results from ECOG 2997. BLOOD. vol. 104, 950A-951A.
10.1182/blood.v104.11.3487.3487
Zhou JB, Li AH, Goldwasser MA, Wang HJ, Dalton V, Lyons C, McBride KD, Sallan SE et al. (2004). Quantitative analysis of minimal residual disease at the completion of induction therapy predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL consortium protocol 95-01. BLOOD. vol. 104, 96A-96A.
10.1182/blood.v104.11.323.323
Vallat LD, Kemper CA, Park Y, Rassenti LZ, Fisher JW, Gribben JG(2004). Reprogramming the Transcriptional Response of Chronic Lymphocytic Leukemia (CLL) Cells: Influencing the Temporal Gene Regulatory Network. Blood vol. 104, (11) 1128-1128.
10.1182/blood.v104.11.1128.1128
Vallat LD, Kemper CA, Park Y, Rassenti LZ, Fisher JW, Gribben JG (2004). Reprogramming the transcriptional response of chronic lymphocytic leukemia (CLL) cells: Influencing the temporal gene regulatory network. BLOOD. vol. 104, 319A-320A.
Byrd JC, Gribben JG, Peterson B, Grever MR, Lozanski G, Lucas DM, Larson RA, Caligiuri MA et al. (2004). Select high risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia (CLL): Preliminary justification for risk-adapted therapy. BLOOD. vol. 104, 139A-139A.
Mauerer K, Zahrieh D, Ansen S, Li AH, Xia ZN, Gribben JG (2004). Somatic hypermutation does not increase the binding affinity of Ig derived peptides to MHC class I or II - Implications for Ig peptide vaccination strategies. BLOOD. vol. 104, 275A-275A.
10.1182/blood.v104.11.960.960
Vallat LD, Park Y, Rassenti L, Gribben JG(2004). Temporal Gene Expression after BCR-Crosslinking Based upon Zap70 Related Genomic Features. Blood vol. 104, (11) 2795-2795.
10.1182/blood.v104.11.2795.2795
Vallat LD, Park Y, Rassenti L, Gribben JG (2004). Temporal gene expression after BCR-crosslinking based upon Zap70 related genomic features. BLOOD. vol. 104, 765A-765A.
Widhopf GF, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ(2004). Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood vol. 104, (8) 2499-2504.
10.1182/blood-2004-03-0818
Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW et al.(2004). ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med vol. 351, (9) 893-901.
10.1056/NEJMoa040857
Gribben JG(2004). Killing malignant but not normal B cells. BLOOD vol. 104, (3) 601-601.
10.1182/blood-2004-05-1776
Rizouli V, Gribben Jg JG(2004). The role of stem cell transplantation in chronic lymphocytic leukemia. Semin Hematol vol. 41, (3) 246-253.
10.1053/j.seminhematol.2004.05.006
Li AH, Rue M, Zhou JB, Wang HJ, Goldwasser MA, Neuberg D, Dalton V, Zuckerman D et al.(2004). Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. BLOOD vol. 103, (12) 4602-4609.
10.1182/blood-2003-11-3857
von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG(2004). CD40 activation: potential for specific immunotherapy in B-CLL. Ann Oncol vol. 15, (6) 853-857.
10.1093/annonc/mdh213
Gribben JG(2004). Graft purging in autologous bone marrow transplantation: A promise not quite fulfilled - The Alvarnas/Forman article reviewed. ONCOLOGY-NY vol. 18, (7) 876-877.
Armstrong SA, Mabon ME, Silverman LB, Li AH, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ(2004). FLT3 mutations in childhood acute lymphoblastic leukemia. BLOOD vol. 103, (9) 3544-3546.
10.1182/blood-2003-07-2441
Letestu R, Ugo V, Valensi F, Radford-Weiss I, Nataf J, Levy V, Gribben JG, Troussard X et al.(2004). Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders. LEUKEMIA vol. 18, (5) 953-961.
10.1038/sj.leu.2403337
Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC et al.(2004). Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. LEUKEMIA LYMPHOMA vol. 45, (2) 315-320.
10.1080/10428190310001593157
Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A et al.(2004). Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion vol. 44, (2) 253-261.
10.1111/j.1537-2995.2004.00666.x
Friedberg JW, Dong DA, Li SG, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG et al. (2004). Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. LEUKEMIA RESEARCH. vol. 28, 139-147.
10.1016/S0145-2126(03)00213-3
Gribben JG(2004). Death of follicular lymphoma cells - the long and the short of it. BLOOD vol. 103, (2) 374-374.
10.1182/blood-2003-10-3492
Li A, Zhou J, Zuckerman D, Rue M, Dalton V, Lyons C, Silverman LB, Sallan SE et al.(2003). Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood vol. 102, (13) 4520-4526.
10.1182/blood-2003-05-1455
Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J et al.(2003). Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. BONE MARROW TRANSPL vol. 32, (12) 1145-1151.
10.1038/sj.bmt.1704289
O'Brien SM, Gribben JG, Thomas DA, Albitar M, Wierda W, Ferrajoli A, Lerner S, Kantarjian HM et al. (2003). Alemtuzumab for minimal residual disease in CLL. BLOOD. vol. 102, 109A-109A.
Zhou JB, Li AH, Diller L, Gribben JG (2003). Application of molecular markers for minimal residual disease detection in neuroblastoma using real-time PCR technology. BLOOD. vol. 102, 215B-216B.
Drandi D, Lee C, Dal Cin P, Gribben JG (2003). Array-based comparative genomic hybridization identifies deletion at 14q32 as a new prognostic marker in chronic lymphocytic leukemia (CLL). BLOOD. vol. 102, 186A-186A.
Gorgun G, Zahrieh D, Drandi D, Neuberg D, Gribben J (2003). Gene expression profiling reveals defects in genes regulating T cell diffentiation and effector pathways in T cells in patients with CLL. BLOOD. vol. 102, 232A-232A.
Rassenti LZ, Toy TL, Huynh L, Greaves A, Gribben JG, Keating MJ, Rai KR, Flinn IW et al. (2003). High similarity between familial and sporadic cases of chroni lymphocytic leukemia. BLOOD. vol. 102, 670A-670A.
Mauerer K, Gorgun G, Drandi D, Gribben JG (2003). Impact of binding affinity to HLA*A0201 on both generation of cytotoxic T cells and their effector function to kill peptide pulsed APCs and CLL cells. BLOOD. vol. 102, 230A-231A.
Gribben JG, Sequist L, Zahrieh D, Neuberg D, Alyea EP, Fisher DC, Freedman AS, Schlossman RL et al. (2003). Outcome following autologous or allogeneic stem cell transplantation in chronic lymphocytic leukemia. BLOOD. vol. 102, 980A-981A.
Li AH, Armstrong S, Rue M, Wang HJ, Zhou JB, Silverman LB, Sallan SE, Gribben JG (2003). V-H gene usage, incomplete DJ(H) recombinations and MLL rearrangements in infant with B-lineage acute lymphoblastic leukemia: Implications for leukemic transformation occurring at an earlier stage of B cell development. BLOOD. vol. 102, 140A-140A.
Grever MR, Dewald GW, Lucas DM, Neuberg DS, Baird ME, Paternoster SF, Brockman SR, Lozanski G et al. (2003). ZAP-70 protein expression varies by interphase cytogenetic group and may predict disease progression to requirement of treatment among select genetic groups in patients with chronic lymphocytic leukemia (CLL). BLOOD. vol. 102, 73A-73A.
Rassenti LZ, Huynh L, Toy TL, Gribben JG, Keating MJ, Rai KR, Flinn IW, Byrd JC et al. (2003). Zap-70 is a more reliable marker of disease progression risk than immunoglobulin mutation status in chronic lymphocytic leukemia. BLOOD. vol. 102, 34A-34A.
Gribben JG (2003). Indolent B-cell malignancies: Immune recognition and antiself. LEUKEMIA & LYMPHOMA. vol. 44, S77-S83.
10.1080/10428190310001623739
Lee C, Drandi D, Dal Cin P, Gribben J (2003). Prognostic markers in CLL by array-based comparative genomic hybridization. AMERICAN JOURNAL OF HUMAN GENETICS. vol. 73, 218-218.
Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG et al.(2003). Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplant vol. 32, (7) 681-686.
10.1038/sj.bmt.1704212
Battle TE, Castro-Malaspina H, Gribben JG, Frank DA(2003). Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis. LEUKEMIA RES vol. 27, (9) 859-863.
10.1016/S0145-2126(03)00009-2
Rizouli V, Gribben JG(2003). Role of autologous stem cell transplantation in chronic lymphocytic leukemia. CURR OPIN HEMATOL vol. 10, (4) 306-311.
10.1097/00062752-200307000-00009
Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J(2003). Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion vol. 43, (5) 614-621.
10.1046/j.1537-2995.2003.00369.x
Gricks CS, Gribben JG(2003). Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity. Curr Pharm Des vol. 9, (23) 1889-1903.
10.2174/1381612033454333
Gricks CS, Zauls AJ, Zahrieh D, Chiaretti S, Krackhardt AM, Neuberg D, Gribben JG (2002). Gene expression profiling demonstrates differential regulation of genes controlling cell cycle progression following CD40 activation in healthy B cells compared to CLL cells. BLOOD. vol. 100, 99A-99A.
Gorgun G, Gribben JG (2002). Induction of autologous Th1 response against CLL cells by addition of exogenous interferon during generation of antigen presenting cells gamma. BLOOD. vol. 100, 591A-591A.
Savage KJ, Weng AP, Kutok JL, Pinkus G, Gribben JG (2002). Loss of CD20 expression following treatment with anti-CD20 monoclonal antibody in chronic lymphocytic leukemia. BLOOD. vol. 100, 364B-364B.
Friedberg JW, Dong DA, Li SG, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG et al. (2002). Oral fludarabine (FMP) is highly active in patients (pts) with previously untreated chronic lymphocytic leukemia (CLL), and leads to increased STAT1 levels in vivo. BLOOD. vol. 100, 388A-388A.
Li AH, Zuckerman D, Zuckerman A, Silverman LB, Sallan SE, Gribben JG (2002). Sequence analysis of clonal IgH and TCR gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: Implications for clinical utility of PCR based methods of minimal residual disease detection. BLOOD. vol. 100, 68A-68A.
Ricca I, Compagno M, Ladetto M, Dell'Aquila M, Bandesan P, Omede P, Rocci A, D'antico S et al. (2002). Telomere length loss in hematopoietic stem cells following two consecutive chemotherapy-induced mobilizing regimens. BLOOD. vol. 100, 146B-146B.
Li AH, Neuberg D, Zuckerman D, Zuckerman A, Silverman LB, Sallan SE, Gribben JG (2002). Utilization of Ig heavy-chain variable, diversity and joining gene segments in childhood acute lymphoblastic leukemia. BLOOD. vol. 100, 760A-761A.
Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG(2002). Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. BLOOD vol. 100, (6) 2123-2131.
10.1182/blood-2002-02-0513
Andersen NS, Donovan JW, Zuckerman A, Pedersen L, Geisler C, Gribben JG(2002). Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol vol. 30, (7) 703-710.
10.1016/s0301-472x(02)00807-x
Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG(2002). T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood vol. 100, (1) 167-173.
10.1182/blood.v100.1.167
Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM et al.(2002). Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. BRIT J HAEMATOL vol. 117, (4) 828-834.
10.1046/j.1365-2141.2002.03535.x
Ladetto M, Omede P, Sametti S, Donovan JW, Astolfi M, Drandi D, Volpato F, Giaccone L et al.(2002). Real-time polymerase chain reaction in multiple myeloma: Quantitative analysis of tumor contamination of stem cell harvests. EXP HEMATOL vol. 30, (6) 529-536.
10.1016/s0301-472x(02)00794-4
Gribben JG(2002). Monitoring disease in lymphoma and CLL patients using molecular techniques. Best Pract Res Clin Haematol vol. 15, (1) 179-195.
10.1053/beha.2002.0191
Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA(2002). Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol vol. 20, (5) 1288-1294.
10.1200/JCO.2002.20.5.1288
Gribben JG(2002). Autologous hematopoietic transplantation for low-grade lymphomas. Cytotherapy vol. 4, (3) 205-215.
10.1080/146532402320219727
Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM et al.(2002). Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant vol. 8, (11) 601-607.
10.1053/bbmt.2002.v8.abbmt080601
Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R et al.(2002). Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant vol. 8, (3) 139-144.
10.1053/bbmt.2002.v8.pm11939603
Webb IJ, Friedberg NW, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H et al.(2002). Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. Biol Blood Marrow Transplant vol. 8, (8) 429-434.
10.1053/bbmt.2002.v8.pm12234168
Gilliland DG, Gribben JG(2002). Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. BIOL BLOOD MARROW TR vol. 8, (1) 9-16.
10.1053/bbmt.2002.v8.pm11846355
Gribben JG(2002). Immunotherapy in the B-cell lymphomas. Cytotherapy vol. 4, (5) 439-440.
10.1080/146532402320776107
Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Caron DA, Gribben JG(2001). Cd40 ligand therapy of lymphoma patients - Reply. J CLIN ONCOL vol. 19, (23) 4352-4353.
Krackhardt AM, Witzens M, Zauls AJ, Barrett P, Chessia M, Gribben JG(2001). Differential expression of newly identified CLL-associated antigenes: Ientification of a novel antigen with cancer-testis like expression pattern and genes with tumor-restricted splice variants. BLOOD vol. 98, (11) 731A-731A.
Rai KR, Coutre S, Rizzieri D, Gribben JG, Flinn I, Rabinowe S, Keating MJ, Campath Study Grp(2001). Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. BLOOD vol. 98, (11) 365A-365A.
Coutre S, Rai KR, Keating MJ, Gribben JG, Flinn I, Rabinowe S, Rizzieri D, Campath Study Grp(2001). Efficacy and safety of alemtuzumab (Campath-1H) used on a compassionate basis in refractory T-PLL. BLOOD vol. 98, (11) 366A-366A.
Krackhardt AM, Witzens M, Zauls AJ, Barrett P, Gribben JG(2001). Identification of novel tumor-associated antigens in CLL - Implications for immunotherapy in CLL. BLOOD vol. 98, (11) 807A-807A.
Zubair AC, Freedman AS, Gribben JG, Friedberg J, Ritz J, Webb IJ(2001). Neutrophil engraftment is a better predictor of long-term hematopoietic function than number of CD34 positive cells infused. BLOOD vol. 98, (11) 323B-323B.
Ladetto M, Omede P, Sametti S, Donovan JW, Drandi D, Giaccone L, Volpato F, Astolfi M et al.(2001). Real time PCR in multiple myeloma: Quantitative analysis of tumor contamination of stem cell harvests. BLOOD vol. 98, (11) 300B-300B.
Lin TS, Zahrieh D, Weller E, Alyea ER, Fisher DC, Gribben JG, Freedman AS, Schlossman RL et al.(2001). Risk factors for CMV reactivation after T-cell depleted allogeneic bone marrow transplantation. BLOOD vol. 98, (11) 480A-481A.
Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Broderick R, Zauls AJ, Gribben JG(2001). Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. BLOOD vol. 98, (10) 2999-3005.
10.1182/blood.v98.10.2999
Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL et al.(2001). CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol vol. 19, (4) 791-798.
10.3892/ijo.19.4.791
Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K et al.(2001). T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood vol. 98, (4) 934-939.
10.1182/blood.v98.4.934
Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD et al. (2001). Phase I study of recombinant human CD40 ligand in cancer patients. JOURNAL OF CLINICAL ONCOLOGY. vol. 19, 3280-3287.
10.1200/JCO.2001.19.13.3280
Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG(2001). Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res vol. 61, (12) 4761-4765.
Schultze JL, Anderson KC, Gilleece MH, Gribben JG, Nadler LM(2001). A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2. BRIT J HAEMATOL vol. 113, (2) 455-460.
10.1046/j.1365-2141.2001.02760.x
Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL et al.(2001). CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol vol. 19, (4) 1152-1159.
10.1200/JCO.2001.19.4.1152
Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, Ricca I, Drandi D et al.(2001). A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol vol. 29, (2) 183-193.
10.1016/s0301-472x(00)00651-2
Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, Ricca I, Drandi D et al.(2000). An extensively valitaded real-time quantitative PCR approach shows a correlation between tumour burden (tb) and successful ex vivo purging in follicular lymphoma (FL) patients. BLOOD vol. 96, (11) 583A-+.
Donovan JW, Zuckerman A, Waters S, Silverman L, Sallan S, Gribben JG(2000). Analysis of residual disease levels in pediatric acute lymphoblastic leukemia by TaqMan quantitative PCR. BLOOD vol. 96, (11) 314A-314A.
Witzens M, Krackhardt AM, Harig S, Zauls AJ, Donovan JW, Gribben JG(2000). Chronic lymphocytic leukemia antigens elicit specific immune responses in the autologous host. BLOOD vol. 96, (11) 513A-513A.
Soiffer RJ, Weller E, Lee SJ, Alyea EP, Schlossman RL, Gribben JG, Ritz J, Antin JH(2000). Comparative outcomes of cyclosporine/methotrexate and CD6+T cell depletion (TCD) as graft-vs-host disease (GVHD) prophylaxis for allogeneic bone marrow transplantation (BMT) from unrelated donors (URD). BLOOD vol. 96, (11) 415A-415A.
Ash S, Donovan JW, Temel J, Zuckerman A, Grupp SD, Diller L, Gribben JG(2000). Detection of minimal residual disease and assessment of stem cell purging by TaqMan real time PCR quantitation of GAGE expression in patients with neuroblastoma. BLOOD vol. 96, (11) 187A-187A.
Krackhardt AM, Witzens M, Donovan JW, Chessia M, Harig S, Gribben JG(2000). Identification of tumor associated genes in CLL by subtractive hybridization. BLOOD vol. 96, (11) 165B-165B.
Harig S, Witzens M, Trojan A, Krackhardt AM, Broderick R, Barrett P, Donovan JW, Gribben JG(2000). Induction of cytotoxic T-cell responses against immunoglobulin derived peptides modified at HLA-A2 binding residues. BLOOD vol. 96, (11) 830A-830A.
Krackhardt AM, Witzens M, Donovan JW, Chessia M, Harig S, Gribben JG(2000). JM1, isolation and characterization of a novel CLL antigen recognized by autologous and syngeneic IgG antibodies. BLOOD vol. 96, (11) 513A-513A.
Widhopf GF, Marathe CM, Rassenti LZ, Byrd JC, Flinn IW, Gribben JG, Kipps TJ(2000). Lack of correlation between immunoglobulin somatic mutation and expression of CD38 in chronic lymphocytic leukemia. BLOOD vol. 96, (11) 367A-367A.
Grdisa M, Tang RP, Delmer A, Levy V, Gribben JG, Ajchenbaum-Cymbalista F(2000). Ligation of CD40 on B-cell chronic lymphocytic leukemia (B-CLL) cells promotes increased survival but does not impair fludarabine induced apoptosis. BLOOD vol. 96, (11) 159A-159A.
Witzens M, Krackhardt AM, Harig S, Donovan JW, Gribben JG(2000). Overexpression of ribosomal proteins in chronic lymphocytic leukemia identified by subtractive hybridization. BLOOD vol. 96, (11) 168B-168B.
Friedberg JW, Neuberg D, Gribben JG, Canning C, Daley JF, Kuhlman C, Koval M, Donovan J et al.(2000). Phase II study of combination immunotherapy with interleukin-2 (IL-2) and rituximab in patients with relapsed or refractory follicular non-Hodgkin's lymphoma (NHL). BLOOD vol. 96, (11) 730A-731A.
Ladetto M, Omede P, Sametti S, Donovan JW, Astolfi M, Giaccone L, Giaretta F, Volpato F et al.(2000). Real time quantitative PCR shows that peripheral blood stem cell (PBPC) harvests are significantly less contaminated than bone marrow (BM) in multiple myeloma patients (MM). BLOOD vol. 96, (11) 154A-154A.
Krackhardt AM, Harig S, Witzens M, Barrett P, Broderick R, Gribben JG(2000). T cell responses in CLL: Superiority of TH2 responses might contribute to reduced cytotoxic autologous antitumor responses. BLOOD vol. 96, (11) 28A-28A.
Return to top